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Abstract 
 
 
Myostatin is a growth and differentiation factor which belongs to the 
transforming growth factor-beta superfamily of genes. Mutations or deletions in 
the myostatin gene leads to the heavy muscling phenotype seen in various cattle 
breeds, including Belgian Blue and Peidmontese, and also in myostatin knock-
out mice. More recently, a human child with the heavy muscling phenotype was 
also found to carry a mutation in the myostatin gene. Conversely, increased 
expression of myostatin has been linked to various muscle wasting conditions 
induced by ageing or disease. Myostatin is therefore regarded as a strong 
inhibitor of muscle growth. In addition, myostatin has also been shown to 
control satellite cell activation post-natally, and is therefore considered a potent 
negative regulator of muscle regeneration and repair.  
 
The ability to block myostatin function has enormous potential in the treatment 
of muscle injuries and various muscle wasting conditions. The Functional 
Muscle Genomics group at AgResearch Ltd. have recently developed several 
myostatin antagonists, produced by truncating the biologically active mature 
myostatin sequence. The following thesis describes the first in vivo study using 
the myostatin antagonist, Mstn-ant4, where its effect on wound healing was 
evaluated using a murine muscle burn injury model. Some promising results that 
Mstn-ant4 could improve muscle wound healing after a severe burn injury were 
obtained. Specifically, Mstn-ant4-treated mice recovered from the burn-induced 
loss of body weight earlier than the saline-treated mice. Mighty gene expression, 
which is a downstream target of myostatin and is involved in muscle 
hypertrophy, was also significantly higher in the burnt muscles of mice treated 
 iv 
 
with Mstn-ant4 compared to saline-treated mice. In addition, histochemical 
analysis indicated that administration of Mstn-ant4 may have been terminated 
too early during the in vivo trial, as reflected by the sudden decrease in centrally 
formed nuclei in the burnt muscles of Mstn-ant4-treated mice at day 14, with the 
last subcutaneous injection of Mstn-ant4 occurring at day 15.  
 
Although no other statistically significant results were obtained by histology, 
immunocytochemistry or gene expression analysis to support these results, it 
would be difficult to conclude that significant results could not be generated 
when the antagonist was used under optimised conditions. That is, further 
studies into the administration schedule of the antagonist need to be undertaken, 
particularly with regard to the frequency of administration and duration of 
treatment. Overall, Mstn-ant4 has significant potential to improve wound 
healing following a severe muscle burn injury.  
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Chapter One: Literature Review 
 
 
The following literature review first describes the various types of muscle 
tissues present in the mammalian body, and then specifically outlines the 
structure and function of skeletal muscle and the mechanisms involved in its 
contraction. The processes involved in myogenesis, from the embryonic origin 
of muscle through to post-natal development are then summarised, including an 
overview of the satellite cell and its role in muscle regeneration. The chapter 
concludes with a review of myostatin, where recent advancements regarding 
myostatin antagonists and their potential role in wound healing are discussed.  
 
1.1. Muscle Physiology 
Three different types of muscle tissues exist in the mammalian body: smooth, 
cardiac and skeletal muscle. Each is characterised by their location and 
structure; for example, cardiac muscle is specifically localised to the heart and is 
striated in appearance. In comparison, smooth muscle is non-striated and is 
located around blood vessels and the walls of organs associated with the 
digestive, respiratory, urinary and reproductive systems. Both cardiac and 
smooth muscles generally consist of mononucleate cells, but cells of cardiac 
muscle are branched. Approximately 55% of the body mass of mammals is 
comprised of skeletal muscle, which is involved in all voluntary movements. 
Skeletal muscle is also striated, but consists of multinucleate cells rather than 
mononucleate ones (Martini, 2002; Zierath & Hawley, 2004). The following 
thesis is based around this last type of muscle tissue, and therefore skeletal 
muscle will be further discussed in the following sections. 
 
 2 
 
1.2. Skeletal Muscle 
1.2.1. Skeletal Muscle Structure  
In skeletal muscle, individual fibres are arranged into bundles referred to as 
fascicles. There are two layers of connective tissue specifically associated with 
these structures, including the perimysium, which surrounds each fascicle; and 
the endomysium, which surrounds each individual muscle fibre within a 
fascicle. In addition, a third layer of connective tissue called the epimysium 
encloses the entire skeletal muscle. Each muscle fibre is divided into smaller 
subunits called myofibrils, and electron microscopy reveals that it is the 
structure of these myofibrils which produces the characteristic striated 
appearance of skeletal muscle. Myofibrils consist of bundles of myofilaments 
that contain specialised contractile proteins organised into sarcomeres. 
Sarcomeres contain two types of protein filaments; thin filaments and thick 
filaments (Figure 1.1A) (Randall et al., 1997; Gordon et al., 2001; Martini, 
2002). Actin is the main component of thin filaments, and it exists as two 
twisted strands of actin molecules with a helical pitch of 36 nm. Nebulin is 
associated with each actin strand and it has recently been proposed that these 
large molecules act as a type of ‘molecular ruler’ involved in length 
specification of the actin filaments during myogenesis (Martini, 1998; 2002; 
McElhinny et al., 2005). Tropomyosin and troponin are the regulatory elements 
of the thin filaments. Chains of tropomyosin molecules join together to form a 
continuous strand that runs along each of the coiled actin strands. Troponin 
consists of three subunits, troponin-C, -I and -T (Tn-C, Tn-I, Tn-T), each of 
which have a specific role during skeletal muscle contraction; Tn-C reversibly 
binds calcium ions, Tn-I binds actin, and Tn-T binds to both Tn-I and Tn-C, as 
well as to tropomyosin.  There is one troponin complex associated with each 
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tropomyosin molecule; tropomyosin blocks myosin binding to seven actins. 
Myosin is the main component of the bipolar thick filament. Each thick filament 
contains approximately 300 myosin molecules, with myosin heads consisting of 
two heavy chains and two light chains projecting in a helical configuration from 
the filament backbone (Squire and Morris, 1998; Gordon et al., 2001).  
 
In the resting sarcomere, distinct regions can be defined based on the 
arrangement of the thick and thin protein filaments. The H-zone (Hele-Sheibe 
zone) encompasses the M-line (middle-line), which is the central region of the 
structure and represents the site where only thick filaments are present. The I-
bands (isotropic-bands) represent the region of the sarcomere where only thin 
filaments are present; these bands are bisected by the Z-line (Zwischenscheibe-
line). The Z-line serves as the anchor point for the thin filaments at either end of 
the sarcomere and therefore the distance between two Z-lines defines the 
sarcomere unit. Finally, the A-band (anisotropic-band) encompasses the H-zone 
and the regions either side where the thick and thin filaments overlap (Figure 
1.1B) (Randall et al., 1997; Gordon et al., 2001; Martini, 2002). 
 
1.2.2. Skeletal Muscle Contraction 
In order to produce force, skeletal muscle contracts via strong binding between 
myosin and actin filaments. The subsequent conformational changes in the 
myosin heads, which project out from the myosin filament, pulls the thin 
filament towards the M-line at the centre of the sarcomere, decreasing the size 
of the H-zones and I-bands (Squire, 1975; Gestrelius & Borgström, 1986; 
Martini, 2002).  
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________________________________________________________________ 
Figure 1.1: The structure of skeletal muscle  
 
A) Skeletal muscle consists of muscle fibres arranged into fascicles. The perimysium surrounds 
each fascicle, while the endomysium surrounds each individual muscle fibre. The epimysium 
encloses the entire skeletal muscle structure. Each muscle fibre contains bundles of 
myofilaments, which consist of repeating sarcomere units. B) Sarcomeres are composed of thick 
and thin filaments which are involved in muscle contraction (Martini, 1998).  
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More specifically, in a low calcium environment, skeletal muscle exists in a 
relaxed state where the conformation of the troponin and tropomyosin molecules 
physically blocks the sites on the actin filament where myosin binds, therefore 
preventing attachment. When calcium is released in response to action potentials 
from innervating muscle neurons, it binds to troponin and initiates the change 
from a relaxed muscle state to an active one. This involves tropomyosin moving 
out of the way as a direct result of calcium binding, therefore exposing the 
myosin binding sites on the actin filament (Squire, 1975; Squire & Morris, 
1998; Gordon et al., 2001). The myosin heads attach to these binding sites, 
forming cross-bridges that pull the filaments past each other, allowing the 
muscle to contract (Tregear & Marston, 1979; Swartz et al., 1990; Martini, 
2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6 
 
1.3. Embryonic Myogenesis 
1.3.1. Somite/Muscle Precursor Formation 
Skeletal muscle development begins with the formation of somites, which are a 
conglomerate of epithelial cells that originate from presomitic mesoderm tissue 
in the mammalian embryo. Formation of these somites occurs in an anterior to 
posterior direction and they lie juxtaposed to either side of the neural tube and 
notochord. The production of these somites appears to be governed by two 
different mechanisms; a type of segmentation clock, which regulates the timing 
of somite formation by initiating oscillating waves of gene expression, and the 
presence of a determination gradient in the presomitic mesoderm. The overall 
process of somite formation is strongly synchronised with embryonic axis 
elongation (Buckingham et al., 2003; Dubrulle & Pourquié, 2004; Brent, 2005; 
Gridley, 2006; Mallo, 2007). 
 
The concept of a segmentation clock was first proposed by Palmeirim et al. 
(1997) who observed that expression of c-hairy1, a gene involved in the Notch 
signalling pathway, occurred as waves in the presomitic mesoderm of the chick. 
More specifically, c-hairy1 expression moved through the presomitic mesoderm 
of the chicken embryo every 90 minutes in a posterior to anterior direction; and 
the frequency of these waves coincided with the formation of a single somite 
(Palmeirim et al., 1997; Hollway & Currie, 2003; 2005; Mallo, 2007). Further 
studies have revealed that numerous other genes involved in the Notch 
signalling pathway also display oscillating expression patterns in the presomitic 
mesoderm, including c-hairy2, deltaC, her1, her7, Hes2, Hes7 and lunatic fringe 
(Pourquié, 2001). Mutations in some of these genes can lead to abnormal 
segmentation, which emphasises the importance of the Notch signalling 
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pathway in somite formation, particularly during the segmentation phase. Recent 
studies suggest that the Wnt signalling pathway may also play a key role in the 
segmentation clock (Aulehla et al., 2003; Mallo, 2007). 
 
Unlike the segmentation clock which regulates the timing of somite formation, 
the determination gradient establishes the position of somite boundaries as the 
individual somites bud off from the presomitic mesoderm. This process is 
achieved by the presence of two opposing morphogen fronts in the presomitic 
mesoderm, an anterior to posterior directed retinoic acid signalling gradient, and 
a posterior to anterior directed fibroblast growth factor (FGF)/Wnt signalling 
gradient (Brent, 2005; Mallo, 2007).  
 
During embryogenesis, the fate of a somite is determined by extrinsic cues 
provided by the surrounding environment; particularly by the neural tube, 
notochord and dorsal ectoderm. The signals produced by these structures initiate 
the division of the somite into the sclerotome, which is ventrally positioned and 
involved in the development of cartilage and bone in the ventral column and 
ribs; and the dermomyotome, which is dorsally positioned. Further patterning 
along the mediolateral axis of the dermomyotome produces distinct medial 
(referred to as the ‘medial lip’), central and lateral partitions. The medial section 
delaminates to form the myotome, which goes on to generate the epaxial 
domain; while the central and lateral sections contain the muscle precursor cells 
for the dermal and hypaxial domains respectively. It is the muscle precursors of 
the epaxial domain that give rise to the musculature of the back; while those of 
the hypaxial domain, consisting of both migrating and non-migrating cell 
populations, gives rise to limb and other body musculature (Marcelle et al., 
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1997; Dietrich et al., 1999; Birchmeier & Brohmann, 2000; Christ & Brand-
Saberi, 2002; Buckingham et al., 2003; Gridley, 2006).  
 
Several of the key molecules and signalling pathways involved in the formation 
of somites and muscle precursors have recently been identified, particularly 
those important for the correct patterning of the somite compartments during 
development. Of these, the coordinated actions of bone morphogenetic proteins 
(BMP), Wnt and sonic hedgehog (Shh) pathways are the most well-documented 
throughout the literature (Zhao & Hoffman, 2004). BMPs belong to the 
transforming growth factor-beta (TGF-) superfamily and approximately 20 
BMP family members are currently recognised (Xiao et al., 2007). One of these, 
BMP-4, is produced by the dorsal neural tube and promotes the upregulation of 
certain Wnt family members, namely Wnt-1 and Wnt-3a.  In turn, these induce 
the expression of another Wnt family member, Wnt-11, which is present in the 
medial lip of the dermomyotome. Overall, this pathway indirectly induces 
formation of the medial lip via Wnt-1 and Wnt-3a, ultimately leading to the 
muscle precursor cells located within this structure relocating from the medial 
lip to the myotome. However, Pourquié et al. (1996) and Marcelle et al. (1997) 
reported that to generate correct patterning in the somite, BMP signalling needs 
to be restricted to certain areas of the somite; therefore suggesting the existence 
of a BMP inhibitor. Noggin has been characterised as the BMP inhibitor present 
in the developing somite (Hirsinger et al., 1997; Krüger et al., 2001). 
Furthermore, Shh, which is produced by the notochord, has been shown to 
directly inhibit Wnt-11 (Marcelle et al., 1997). 
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1.3.2. Migration to the Limb Bud 
The migration phase of muscle development begins with the delamination of 
muscle precursor cells from the hypaxial dermomyotome, at a location opposite 
to the target limb bud. This is followed by the movement of these cells into a 
position in the limb bud where the formation of specific muscle masses will be 
initiated. The presence of the tyrosine kinase receptor, c-Met, and its associated 
ligand, scatter factor/hepatocyte growth factor (SF/HGF) are essential for both 
the delamination and migration of the muscle precursor cells. This receptor 
originates in non-somitic mesodermal cells, and transcription of the c-Met gene 
is mediated through the transcription factor Pax3 (Dietrich et al., 1999; 
Buckingham et al., 2003).  The importance of both c-Met and Pax3 in precursor 
cell migration and muscle development is clearly shown in mutant mice, where 
embryos lacking functional c-Met or SF/HGF fail to develop skeletal muscle. 
Furthermore, in addition to a lack of limb muscle development, muscle 
precursor cells of Pax3-mutant mice fail to even delaminate from the hypaxial 
dermomyotome and thus fail to initiate migration (Tajbakhsh et al., 1997; 
Dietrich et al., 1999; Birchmeier & Brohmann, 2000; Buckingham et al., 2003; 
Yusuf & Brand-Saberi, 2006).  
 
Ladybird homeobox 1 (Lbx1) is another transcription factor that plays a key role 
during the migration of cells from the somite to the limb bud, and its expression 
is thought to depend on the presence of Pax3. Lbx1 is upregulated before 
delamination begins, its expression is maintained throughout the migration 
period, and is then downregulated once muscle-specific gene expression is 
activated in the limb bud (Christ & Brand-Saberi, 2002). In mutant Lbx1 mouse 
embryos, the muscle precursor cells are properly formed and delaminate from 
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the dermomyotome in the same manner as that seen in wild-type embryos. 
However, the precursor cells display abnormal migration patterns, tending to 
remain in close proximity to the somites, where alternative cell fates may be 
adopted. Yet, although there is a significant loss of muscle mass in Lbx1 
mutants, it is much less severe when compared to the muscle phenotypes seen in 
the Pax3-mutant and c-Met-mutant mice (Birchmeier & Brohmann, 2000; Gross 
et al., 2000; Buckingham et al., 2003; Yusuf & Brand-Saberi, 2006).  
 
The actual regulation of the Pax3 and Lbx1 genes during muscle development is 
not well understood.  Gross et al. (2000) proposed that Pax3 and Lbx1 are co-
expressed in all migrating hypaxial muscle precursors, and several studies 
suggest that Lbx1 is located downstream of Pax3. However, Buckingham et al. 
(2003) presented the alternative view that Lbx1 can be independently activated. 
In addition, Wnt-6, which is produced by the surface ectoderm, has been 
identified as a potential candidate for the activation of Pax3; while members of 
the FGF family are thought to be involved in Lbx1 regulation (Birchmeier & 
Brohmann, 2000; Buckingham et al. 2003). 
 
An additional homeobox transcription factor has also been implicated in the 
migration of muscle progenitor cells to the limb bud, namely Msx1. Msx1 is 
able to inhibit myogenesis, therefore retaining the muscle precursor cells in an 
undifferentiated state necessary for migration (Houzelstein et al., 1999). Further 
conditions required for the migration of muscle precursor cells include the 
presence of the cell-adhesion molecules, N-cadherin and fibronectin, and the 
extracellular spaces also need to be large enough to accommodate the migrating 
cells. In addition, the tyrosine kinase receptor EphA4, and its associated ligand 
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ephrinA5, are needed to guide the cells into the appropriate locations in the limb 
buds (Christ & Brand-Saberi, 2002). 
 
1.3.3. Muscle Differentiation and Growth in the Limb Bud 
There are two general steps required to complete the myogenic programme once 
the muscle precursor cells have migrated to the limb buds. These include 
commitment of the precursor cells to the myogenic lineage, which involves the 
formation of myoblasts; and then these myoblasts undergo terminal 
differentiation to form myotubes, providing the basis for muscle growth.  During 
these stages, Pax3 and Lbx1 expression significantly decreases, while the 
expression of muscle-specific and differentiation markers increase. These 
markers include the myogenic regulatory factors (MRFs) and the MEF2 family 
of myocyte enhancer-binding factors, which interact with each other to regulate 
the transcription of muscle-specific differentiation genes (Yun & Wold, 1996; 
Wang & Jaenisch, 1997).  
 
1.3.3.1. The MRFs 
MyoD, myogenin, Myf-5 and MRF4 comprise the group of basic helix-loop-
helix (bHLH) transcription factors, collectively referred to as the MRFs. Each of 
these MRF family members contains a conserved DNA binding region, which 
specifically targets the Ephrussi–box (E-box) consensus sequences present in 
most muscle-specific genes (Tapscott & Weintraub, 1991; Ludolph & 
Konieczny, 1995). During skeletal muscle formation, the trend of MRF 
expression is somewhat hierarchical, with Myf-5 appearing first in the mouse 
somite at embryonic day 8 (E8), followed by myogenin and MyoD emerging in 
the myotome at E8.5 and E10.5 respectively; concluding with the transient 
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expression of MRF4 in the myotome between E9 and E11.5 (Zhang et al., 
1995). With regard to limb bud development, Myf-5 expression is initiated in 
the limb buds at E11, myogenin and MyoD appear soon after at E11.5, and 
MRF4 expression emerges much later, when it is expressed in differentiated 
muscle fibres (Zhang et al., 1995).  
 
From these timelines it is generally accepted that Myf-5 and MyoD are involved 
in regulating the determination process resulting in the multipotent somite cells 
being committed to the myogenic lineage; while myogenin and MRF4 are 
involved in the initiation of myoblast differentiation, which occurs later in the 
myogenic programme. Therefore Myf-5 and MyoD are often referred to as the 
primary MRFs, while myogenin and MRF4 are referred to as the secondary 
MRFs (Rudnicki et al., 1993; Borycki & Emerson, 1997).  
 
Since these initial observations, phenotypes of knock-out mouse models have 
been used to further study the MRFs and to clarify their roles in skeletal muscle 
formation. Rudnicki et al. (1992; 1993), observed that both Myf-5-null mice and 
MyoD-null mice displayed normal skeletal muscle development; whereas Myf-
5/MyoD double knock-out mice failed to produce any skeletal muscle fibres or 
myoblasts at all, rendering them immobile at birth and resulting in death soon 
after. This suggests a functionally interchangeable role for Myf-5 and MyoD, as 
the presence of either one can successfully facilitate the development of skeletal 
muscle. However, additional studies identified a significant rib defect in the 
Myf-5 mutants and a reduced capacity for muscle regeneration in the MyoD 
mutants, as well as an overall delay in their skeletal muscle development (Wang 
& Jaenisch, 1997). Recent evidence has also shown Myf-5 to be genetically 
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linked to MRF4, and therefore the generation of Myf-5-null mice consequently 
influences MRF4 expression in these animals. For that reason, it has been 
proposed that along with MyoD and Myf-5, MRF4 should also be classified as a 
skeletal muscle determination gene, though this is still widely debated (Kassar-
Duchossoy et al., 2004).  
 
In contrast to Myf-5-null or MyoD-null mice, which still display normal skeletal 
muscle development, mice with a targeted homozygous mutation for myogenin 
exhibit severe skeletal muscle defects. More specifically, migrating myoblasts 
are still present in myogenin-null mice, but these fail to terminally differentiate 
into myotubes, and therefore do not meet the requirements for successful muscle 
development. However, there are some residual muscle fibres present in the 
mice at birth, suggesting that a myogenin-independent pathway for muscle 
differentiation may exist (Hasty et al., 1993; Rawls et al., 1998). Additional 
complications in these mutant mice include the presence of extensive adipose 
tissue, particularly in the dorsal neck region, abnormal curvature of the spine 
and a deformed rib cage. Ultimately these problems lead to the death of 
myogenin-null mice immediately following their birth (Hasty et al., 1993; 
Nabeshima et al., 1993; Zhang et al., 1995; Wang & Jaenisch, 1997). The 
migrating myoblasts of myogenin-null mice express Myf-5 and MyoD, therefore 
supporting the idea that myogenin functions at a later time point in the myogenic 
pathway than the primary myogenic factors. In addition, there is a minimal level 
of MRF4 expression in myogenin-null mice, which is also consistent with the 
proposed myogenic pathway, where myogenin acts before MRF4 during muscle 
development (Zhang et al., 1995). This contradicts the earlier idea that MRF4 
should be classified as a skeletal muscle determination gene.  
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Combined myogenin/MyoD-null mutations and myogenin/Myf-5-null mutations 
have also been investigated. Results indicate that similar phenotypes were 
produced by these combinations as those seen in mice deficient in the individual 
factors (Rawls et al., 1998). However, Wang and Jaenisch (1997) brought 
attention to the varying expression patterns of the MRFs. In particular, 
expression of Myf-5 and MyoD first appear in the dorsal-medial half and the 
ventral-lateral half of the myotome respectively, while myogenin and MRF4 
expression is detected throughout the whole myotome. Therefore, the authors 
discovered that when myogenin is expressed in a similar temporal and spatial 
pattern to Myf-5, it is able to substitute the role of this regulatory factor in
myogenic lineage determination, though not as effectively.  
 
Finally, like Myf-5 and MyoD, MRF4-null mice are also viable, displaying 
normal skeletal muscle development and a normal range of movement 
immediately after birth. However, they too show severe rib defects which 
ultimately leads to their death shortly after birth. Interestingly, MRF4-null mice 
show significant upregulation of myogenin (up to five-fold) suggesting that this 
myogenic regulatory factor may be compensating for the loss of MRF4 in the 
mice (Zhang et al., 1995; Arnold & Braun, 1996). However, if MRF4 and 
myogenin had truly overlapping functions a more severe phenotype in the 
MRF4/myogenin double mutant mice would be expected compared to the 
phenotypes of MRF4-null or myogenin-null mice alone. Rawls et al. (1998) 
reported the MRF4/myogenin double mutant phenotype and the phenotyope of 
myogenin-null mice alone to be very similar. In contrast, the authors discovered 
that although MRF4-null or MyoD-null mice were viable at birth and show 
normal skeletal muscle development, MRF4/MyoD double mutant mice 
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displayed a severe muscle deficiency similar to myogenin-null mice, indicating 
a potential compensatory role for MRF4 and MyoD during myogensis (Rawls et 
al., 1998). 
 
1.3.3.2. The MEF2 Family 
As previously mentioned in Section 1.3.3, the MEF2 family also plays a key 
role during myogenesis, with the majority of muscle-specific genes containing 
the MEF2 binding site, CTA(A/T)4TAG, in their control regions. This group of 
proteins was originally identified from the nuclei of skeletal muscle myotubes, 
after Gossett and colleagues (1989) observed their ability to specifically bind 
A/T-rich sequences in the muscle creatine kinase (MCK) gene promoter (Brand, 
1997).  The vertebrate MEF2 family is comprised of four members: MEF2A, 
MEF2B, MEF2C and MEF2D. Their capacity for high-affinity DNA binding 
and dimerisation is facilitated through two interacting domains, a distinct 29 
amino acid MEF2 domain, and a highly conserved 57 amino acid motif referred 
to as the MADS-box. The presence of a MADS-box in these genes provides the 
basis for their inclusion in the MADS-box superfamily of transcriptional 
regulators, named after the founding members, minichromosome maintenance 1 
(MCM1), agamous, deficiens and serum response factor (SRF). The MADS-box 
transcriptional regulators are involved in a wide range of biological functions, 
including the pheromone response in yeast, flower development in plants, 
tracheal development in Drosophila and, as discussed here, in the regulation of 
muscle-specific genes (Shore & Sharrocks, 1995; Brand, 1997; Black & Olson, 
1998; Perry & Rudnicki, 2000).  
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Unlike the MRFs, MEF2 genes are expressed in a wide range of lineages, 
including skeletal, cardiac and visceral muscle, as well as in neural cells, T cells 
and fibroblasts (Molkentin & Olson, 1996a; 1996b; Brand, 1997; Naya & Olson, 
1999). During skeletal muscle development there is a significant overlap 
between MRF and MEF2 expression. MEF2 also shows a hierarchical pattern of 
expression like that seen in the MRFs. More specifically, MEF2C appears first 
in the developing myotome at E8.5, closely followed by the expression of 
MEF2B at E9, and then MEF2A and MEF2D at E9.5 (Molkentin & Olson, 
1996a). Interestingly, the MEF2A, MEF2B and MEF2D transcripts are 
expressed ubiquitously after birth, while MEF2C is restricted to skeletal muscle, 
brain and spleen tissues (Molkentin et al., 1995).   
 
Consistent with other MADS-box proteins, the MEF2 family members interact 
with a diverse range of transcription factors to initiate a plethora of different 
gene expression programmes. Of these, interactions with the MRFs have been 
the most extensively studied, with many authors concluding that these two 
transcription factor families act as co-regulators during skeletal muscle 
development (Black & Olson, 1998).  Among the first observations made 
involved 10T1/2 cells, a multipotential cell line derived from 14- to 17-day 
whole mouse embryos. It was originally established by Reznikoff et al. (1973) 
and has been widely used in molecular biology ever since (Pinney & Emerson, 
1989). Specifically, the forced expression of MRFs in 10T1/2 cells activated 
MEF2 DNA binding activity, suggesting that MEF2 factors lie downstream of 
MRFs in the skeletal muscle regulatory pathway. However, both myogenin and 
MRF4 contain MEF2 binding sites in their promoters and these are involved in 
the expression of muscle-specific genes. Therefore, MEF2 and the MRFs appear 
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to regulate the expression of each other through complex reciprocating circuits 
(Molkentin et al., 1995; Naidu et al., 1995; Molkentin & Olson, 1996a; Black & 
Olson, 1998). In addition, Molkentin et al. (1995), and supporting studies by Yu 
et al. (1992) and Ornatsky et al. (1997), reported that MEF2 factors by 
themselves, were unable to activate myogenesis in transfected 10T1/2 and 3T3 
fibroblasts; with 3T3 being a standard fibroblast cell line derived from Swiss 
mouse embryo tissue (Todaro et al., 1964). However, muscle-specific gene 
expression was successful when both MEF2 and MRFs were present, with the 
authors observing a 3- to 4-fold increase in the number of myosin heavy chain 
(MHC) positive cells. This suggests MEF2 and MRFs could be acting 
synergistically to activate myogenesis. 
 
 Although a vertebrate loss-of-function model for MEF2 factors is yet to be 
developed, analysis of loss-of-function mutations in a single MEF2 gene, D-
MEF2, in Drosophila supported the idea that MEF2 is necessary for skeletal 
muscle development. More specifically, this mutation resulted in the complete 
absence of differentiated skeletal, cardiac and visceral muscle cells. 
Supplementary studies revealed that nautilus expression, a Drosophila homolog 
of MyoD, did occur at the correct time and location in the D-MEF2-mutant 
embryos, but it was unable to initiate the expression of muscle-specific genes; 
therefore suggesting that D-MEF2 is particularly important for nautilus function 
(Molkentin et al., 1995; Olson et al., 1995; Molkentin & Olson, 1996b; Black & 
Olson, 1998).  
 
The actual mechanism of synergy employed by these two transcription factor 
families to regulate skeletal muscle development is still under investigation.  It 
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is currently accepted that MEF2 factors only associate with the heterodimers 
formed from myogenic bHLH proteins and non-myogenic E proteins, such as 
E12, and not with E protein homodimers. E12-MRF heterodimers can convert 
non-muscle cells to differentiated myotubes, while E12 homodimers cannot. 
Two key amino acid residues located in the centre of the MRF basic domain, 
alanine and threonine, have been identified as the determinants of MRF 
myogenic activity. Substituting these two myogenic residues with the two 
asparagines located in the corresponding region of E12 abolishes the myogenic 
activity of the MRFs without affecting DNA binding. On the other hand, 
generation of a revertant mutant, where the substituted asparagine residues are 
mutated back to the alanine and threonine residues, restores full myogenic 
activity in the MRFs. This suggests it is the alanine and threonine residues that 
are crucial to facilitate the interaction between MRFs and MEF2, by enabling a 
specific conformational change in the MRFs to allow the recruitment of MEF2 
as a co-regulator (Arnold & Winter, 1998; Black et al., 1998; Naya & Olson, 
1999).  
 
A two-step model for successful transcriptional activation by the synergistic 
actions of MRFs and MEF2 has emerged. Specifically, MEF2 first binds to the 
DNA-bound MRF and relays its activation signal to the transcriptional 
activation domain of the MRF. This MRF domain then transmits both its own 
activation signal and that of MEF2 to the basal transcriptional machinery and an 
active transcriptional complex is generated. In addition to being involved in the 
association of MRFs and MEF2, the amino acids alanine and threonine also play 
an important role in facilitating the transmission of activation signals from the 
MRFs (Black et al., 1998; Black & Olson, 1998).  
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1.3.4. The Cell Cycle and Myogenesis 
As the muscle precursor cells terminally differentiate and fuse together to form 
mature myotubes, they irreversibly withdraw from the cell cycle (Walsh & 
Perlman, 1997). This is a complex regulatory circuit which methodically guides 
the cell through a series of events, ultimately leading to mitosis and the 
generation of two “daughter cells”. The cell cycle has four characteristic phases; 
the S-phase (synthesis-phase) where duplication of genetic material occurs; the 
M-phase (mitosis-phase) where the duplicated chromosomes are evenly 
distributed to the two daughter cells; and G1 and G2, which are the two ‘gaps’ 
antecedent to the S-phase and M-phase, respectively. One of the key protein 
families involved with the transition of a cell through each phase of the cycle is 
the cyclin-dependent kinases (CDKs), which belong to the serine/threonine 
family of protein kinases. Various checkpoints have been developed to monitor 
the progress of a cell through the cell cycle and to specifically ensure that 
critical events, such as DNA replication and chromosome segregation, are 
completed successfully before entering into the next phase. These checkpoints 
have the ability to either permanently arrest defective cycles, or temporarily 
pause the cycle while adequate repairs and maintenance are carried out (Schafer, 
1998; Tessema et al., 2004).  
 
The generation of new muscle fibres, through the fusion of myoblasts and 
subsequent myotubes, occurs in two distinct waves characterised by specific 
temporal patterns, structural fibre morphology and gene expression. The first 
wave of fibres, termed primary fibres, are widely distributed throughout the 
limb, providing the foundation for further fibre development by defining 
specific characteristics of the muscle such as type, shape and location. A rapid 
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increase in diameter (not associated with nucleation) is one of the key 
identifying features of the primary fibres, along with the ‘doughnut’ shape 
observed when the fibres are transversely sectioned. In comparison, secondary 
fibres form on the surface of primary fibres and rapidly increase in number and 
nucleation (Wigmore & Dunglison, 1998; Christ & Brand-Saberi, 2002; Abmayr 
et al., 2003).  
  
In vertebrates, the process of myoblast fusion, which ultimately leads to 
myotube and subsequent skeletal muscle formation, consists of several 
characteristic stages. Specifically, myoblasts that have been induced to fuse first 
undergo myoblast recognition, where they become weakly associated with each 
other. This is followed by the adherence phase, where associations within the 
cell mass become stronger, therefore making it more difficult to disrupt the 
aggregate. The membrane union stage concludes the overall process, with 
myoblasts now being fully fused together. Several molecules are involved with 
adhesive interactions prior to myoblast fusion, including neural cell adhesion 
molecule (NCAM) which is upregulated in cells as the formation of myotubes 
commences. M-cadherin and N-cadherin are also thought to be involved, based 
on their changing expression levels during myoblast fusion and myotube 
formation, and the observation that cadherin monoclonal antibodies and 
polyclonal antisera inhibit myoblast association, therefore reducing myotube 
formation. However, both M-cadherin-null and N-cadherin-null mice show 
normal skeletal muscle development, contradicting the idea that these molecules 
play a key role during myoblast fusion (Abmayr et al., 2003).  
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Several other molecules implicated in the regulation of myoblast fusion have 
also been recently discovered. For example, melanoma cell adhesion molecule 
(M-CAM) is significantly downregulated in human myoblasts during fusion and 
in vitro studies show that inhibition of M-CAM expression using an M-CAM 
RNA knockdown technique led to enhanced levels of myoblast fusion (Cerletti 
et al., 2006). Horsley et al. (2003) reported a novel role for Interleukin-4 (IL-4), 
where signalling by the transcription factor NFATc2 in newly developed 
myotubes initiates IL-4 expression and secretion, helping to facilitate the fusion 
of myoblasts with pre-existing myotubes (Chargé & Rudnicki, 2003). Finally, 
myoferlin is significantly upregulated in myoblasts at the site of their fusion 
with pre-existing myotubes. Knocking this gene out of the genome produced 
null mice which still underwent the primary fusion events but displayed defects 
in their ability to form large myotubes, suggesting a role for myoferlin during 
the later stages of myogenesis (Doherty et al., 2005).  
 
1.3.5. Skeletal Muscle Fibre Types 
Primary and secondary skeletal muscle fibres can be further divided into 
different fibre types, including fast, slow and intermediate fibres. These can 
have different nomenculture depending on the species being referred to, but for 
the purposes of this thesis the murine nomenculture is used. Fast fibres, 
otherwise known as fast-twitch glycolytic or Type IIB fibres, are defined by 
their fast contraction speeds and large cross-sectional diameter. Energy 
production is predominantly by glycolysis, but large quantitities of adenosine 
triphosphate (ATP) are used during the contraction of fast fibres, and therefore 
any prolonged activity is maintained by anaerobic metabolism. However, fast 
fibres ultimately succumb to fatigue quite rapidly. In contrast, slow fibres, 
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which are also referred to as slow-twitch oxidative or Type I fibres, have 
significantly slower contraction speeds, taking up to three times as long to 
contract compared to a fast fibre. Unlike fast fibres, slow fibres contain large 
oxygen reserves bound to myoglobin, and coupled with the extensive capillary 
networks and increased numbers of mitochondria present in muscles composed 
of slow fibres, aerobic metabolism enables them to contract over longer periods 
of time compared to fast fibres.  The intermediate fibres, also known as fast-
twitch oxidative or Type IIA fibres, are the other class of skeletal muscle fibres. 
As their name suggests, they have properties midway between the fast and slow 
fibres. The original fibre type of the primary fibres during skeletal muscle 
development is slow, but some later change into fast fibres. Conversely, all 
secondary fibres start out being fast, and then some change into slow fibres. 
These conversions are mediated by a range of different factors and are restricted 
to specific locations in the developing limbs (Pullen, 1977a; 1977b; Martini, 
1998; Wigmore & Dunglison, 1998). 
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1.4. Post-Natal Myogenesis  
1.4.1. The Satellite Cell 
1.4.1.1. Satellite Cell Morphology, Distribution and Origin 
The majority of post-natal skeletal muscle growth, maintenance, repair and 
regeneration is facilitated through satellite cells which are specialised myogenic 
precursors located between the sarcolemma and basal lamina of mature skeletal 
muscle fibres (Hawke & Garry, 2001). Although originally considered 
unipotent, numerous studies have now shown satellite cells to be multipotent, 
with the ability to differentiate into myogenic, osteogenic and adipogenic 
lineages (Asakura et al., 2001). In addition to their characteristic position at the 
periphery of the fibre, satellite cells contain only a small amount of cytoplasm; 
they also have a reduced organelle content and a smaller nuclear size with 
significantly higher levels of heterochromatin than euchromatin, compared to 
fibre myonuclei.  This morphology is consistent with the mitotically quiescent 
state that satellite cells predominantly adopt (Schultz, 1976; Hawke & Garry, 
2001; Chargé and Rudnicki, 2004; Holterman & Rudnicki, 2005). These 
populations of cells have since been identified in all types of vertebrate skeletal 
muscle (Holterman & Rudnicki, 2005). However, within skeletal muscle, 
satellite cells show an unequal distribution between the different fibre types, 
with a higher proportion associated with the slow muscle fibres than the fast 
muscle fibres based on calculations using total nuclei number in muscle cross 
sections (Schmalbruch & Hellhammer, 1977; Gibson & Schultz, 1982; Chargé 
and Rudnicki, 2004).  
 
These unique populations of cells were first discovered in the leg muscle of 
frogs (Katz, 1961; Mauro, 1961), and Mauro (1961) hypothesised that satellite 
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cells were simply dormant myoblasts left over from embryonic muscle 
development. Therefore, instead of fusing with other myoblasts to form 
myotubes and subsequent myofibres, solitary myoblasts remained in a quiescent 
state ready to provide additional nuclei if required during muscle growth and 
repair. Since this original proposal, the origin of satellite cells has been widely 
debated, with two main arguments emerging. The idea of a somitic origin is 
supported by traditional chimeric avian transplantation studies, where the 
development of quail-derived embryonic somites that had been introduced into a 
host chick embryo were found to produce migrating somitic cells that 
contributed to both the developing limbs and the post-natal skeletal muscle 
satellite cell population of the chick. This led to the conclusion that all myogenic 
cell lineages, including satellite cells, had a universal somitic origin (Armand et 
al., 1983). However, later studies challenged this idea in favour of an endothelial 
origin. De Angelis et al. (1999) isolated cells from mouse embryonic dorsal 
aorta and discovered their morphology and gene expression profiles closely 
resembled those of satellite cells. Furthermore, when these cells were 
transplanted into newborn mice, they worked in conjunction with the 
populations of satellite cells already present in the skeletal muscle, and 
successfully participated in post-natal muscle growth and regeneration. This 
therefore suggests there could be an endothelial origin for the satellite cell, or 
alternatively a derivation from a common satellite and endothelial cell precursor 
(Hawke & Garry, 2001).   
 
1.4.1.2. Satellite Cell Quiescence 
As previously mentioned in Section 1.4.1.1, satellite cells usually reside in a 
quiescent state, which is represented as G0 in the cell cycle. Quiescence is 
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typically characterised by minimal amounts of cell division, gene expression and 
protein synthesis (Dhawan & Rando, 2005; Le Grand & Rudnicki, 2007); 
however, recent lymphocyte studies by Yusuf and Fruman (2003) have 
challenged the original view that quiescence simply represents an inactive basal 
state depleted of any activation signals. Instead these authors suggested this state 
may actually be under active transcriptional control with several key regulatory 
molecules promoting the quiescent phenotype, such as lung Krüppel-like factor 
(LKLF) and the Forkhead Box (FOX) proteins.  
 
Extensive histological studies carried out by Irintchev et al. (1994) led to the 
discovery that the calcium-dependent cell adhesion molecule, M-cadherin, is 
widely expressed among quiescent satellite cells. Further studies by Beauchamp 
et al. (2000) also identified CD34 and Myf-5 as novel markers expressed by the 
majority of these cells. The small proportion of satellite cells that do not express 
these markers are thought to be involved in maintaining the rest of the lineage-
committed satellite cell population. CD34 is a widely accepted marker of adult 
hematopoietic stem cells that is commonly used in the isolation of these cells 
from blood and bone marrow. Two isoforms of CD34 exist. There is the 
truncated version, which lacks the three phosphorylation sites present in the 
intracellular domain of the full-length CD34 protein, and this is expressed in 
quiescent satellite cells. However, upon activation of the satellite cells, 
alternative splicing leads to a change in expression from the truncated form to 
the full-length version of CD34.  
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1.4.1.3. Satellite Cell Activation, Proliferation and Differentiation 
Satellite cells are predominantly activated in response to trauma, weight-bearing 
or exercise-induced muscle injury, or for maintenance during muscle growth. As 
discussed earlier, this process involves the exit of satellite cells from the 
quiescent state and their re-entry into the cell cycle, specifically transitioning 
from the G0 to G1 phase. Following activation, these cells undergo numerous 
rounds of proliferation before continuing along the myogenic lineage, where 
they terminally differentiate and amalgamate together to form new myotubes 
and subsequent myofibres, or alternatively migrate and fuse to the damaged 
sections of pre-existing muscle fibres (Figure 1.2)  (Morgan & Partridge, 2003; 
Chargé & Rudnicki, 2004; Dhawan & Rando, 2005). Reminiscent of skeletal 
muscle development from muscle precursor cells, the activation of satellite cells 
is accompanied by the expression of myogenic regulatory factors. Cooper et al. 
(1999) demonstrated that during the first 24 hours after activation, satellite cells 
upregulate MyoD or Myf-5 independently; and then these same factors are co-
expressed in the subsequent 24 hour period. Myogenin expression follows later, 
with a significant proportion of activated satellite cells eventually expressing all 
four MRFs concurrently (Smith et al., 1994; Cornelison & Wold, 1997; 
Holterman & Rudnicki, 2005).   
 
In addition to MRFs, numerous growth factors also function as positive and 
negative regulators of satellite cells and these factors are often produced by the 
injured fibres themselves, or by cells associated with the immune response. One 
of the founding experiments carried out in this field was by Bischoff (1986), 
who demonstrated the successful activation of quiescent satellite cells in 
cultured crushed muscle extract. Tatsumi et al. (1998) later identified SF/HGF  
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Figure 1.2: Satellite cell function 
 
In response to myotrauma, satellite cells are activated to exit the quiescent state and re-enter the 
cell cycle where they proliferate and differentiate to repair muscle. Some satellite cells may 
undergo self-renewal to replenish the quiescent satellite cell pool (Hawke and Garry, 2001).  
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as the stimulus in the crushed muscle extract that was responsible for the 
satellite cell activation. Quiescent satellite cells express the tyrosine kinase 
receptor c-Met, which binds SF/HGF.  
 
Furthermore, in the absence of muscle injury or trauma, the injection of SF/HGF 
into the tibialis anterior (TA) muscle of adult mice efficiently activated 
quiescent satellite cells. This led to the implication of nitric oxide (NO) in 
satellite cell activation, as this molecule is suggested to be involved in the 
release of SF/HGF from the extracellular matrix. Anderson (2000) reported a 
significant decrease in satellite cell activation post-trauma when nitric-oxide 
synthase-I (NOS-I), the molecule in the body which produces NO, was inhibited 
(Holterman & Rudnicki, 2005).   
 
As well as the HGFs, insulin-like growth factors (IGFs), FGFs, and members of 
the TGF- family have been extensively studied and shown to have varying 
effects on the satellite cell population in vitro (Allen & Boxhorn, 1989; Zentella 
& Massagué, 1992; Doumit et al., 1993; Johnson & Allen, 1995; Sheehan & 
Allen, 1999; Yablonka-Reuveni et al., 1999b; Chakravarthy et al., 2000). Allen 
and Boxhorn (1989) reported a significant increase in the differentiation of 
satellite cells in the presence of IGF-1, while FGF increased proliferation and 
decreased differentiation, and TGF- decreased proliferation and inhibited 
differentiation. Furthermore, Sheehan and Allen (1999) studied eight members 
of the FGF family, FGF1, 2, and 4-9, and discovered that only FGF1, 2, 4, 6 and 
9 significantly increased the proliferation of adult rat muscle satellite cells, 
while FGF5, 7 and 8 did not induce any mitogenic activity in the cells. In 
addition to their individual effects on the satellite cell population, HGFs, IGFs, 
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FGFs and TGF- family members also appear to have a synergistic relationship 
with each other, and with other growth factors present in skeletal muscle. For 
example, the interaction of FGFs with IGF-1 or the platelet-derived growth 
factor-BB (PDGF-BB), results in significantly higher levels of satellite cell 
proliferation than the sum produced from each individual factor (Doumit et al., 
1993). Similar observations were made when both HGF and either FGF2, 4, 6 or 
9 were present (Sheehan & Allen, 1999). 
 
Due to the complexity of the multi-step activation process and the numerous 
molecules involved, the exact signalling pathways and mechanisms which 
regulate the satellite cell population are yet to be fully defined. However, along 
with playing a key role in somite and muscle precursor formation, the Notch 
signalling pathway also appears to be involved in satellite cell activation. 
Conboy and Rando (2002) demonstrated that Notch-1 becomes activated as 
satellite cells transition from the G0 to G1 phase of the cell cycle; and that 
inhibition of Notch-1 by the cytoplasmic protein, Numb, prevents satellite cell 
activation. In addition, two different pathways are thought to be utilised by IGF-
1 during satellite cell regulation, with the calcineurin/NFAT, mitogen-activated 
protein (MAP) kinase pathway implicated in satellite cell proliferation; and the 
phosphatidylinositol-3-OH kinase pathway involved with satellite cell 
differentiation (Coolican et al., 1997; Hawke & Garry, 2001). FGFs have also 
been shown to use the MAP kinase signalling pathway. Jones et al. (2001) 
identified the extracellular signal-regulated kinase (ERK) subfamily of the MAP 
kinase pathway as important for FGF-induced satellite cell proliferation, 
particularly the ERK1/2 signalling. However, the pathway involved in the 
depression of satellite cell differentiation by FGFs is not currently known 
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(Robinson & Cobb, 1997; Hawke & Garry, 2001). Finally, TGF- family 
members use the Smad proteins for their signalling pathways, as discussed in 
Section 1.6.2 of this thesis (Whitman, 1998; Hawke & Garry, 2001).  
 
1.4.1.4. Satellite Cell Self-Renewal 
To prevent depletion of the satellite cell pool after repeated rounds of skeletal 
muscle repair and regeneration, it is suggested that satellite cells have the ability 
to self-renew. This idea is supported by radiolabel-tracing experiments which 
have clearly demonstrated the contribution of activated satellite cells to both 
new myonuclei and the quiescent satellite cell pool after muscle injury (Chargé 
& Rudnicki, 2004).  
 
Different models have been proposed to explain the process of satellite cell self-
renewal. Firstly, the stochastic model where each activated satellite cell divides 
symmetrically, with one of the subsequent daughter cells being able to 
relinquish its position in the differentiation programme and adopt a quiescent 
state, while the remainder continues along the myogenic lineage to terminal 
differentiation. Alternatively, each activated satellite cell may first divide 
asymmetrically producing one quiescent daughter cell to replenish the satellite 
cell pool while the other is committed to the myogenic pathway. The progeny 
which proceed with normal myogenesis may then undergo asymmetric divisions 
themselves to produce further satellite cells (Figure 1.3) (Chargé & Rudnicki, 
2004; Dhawan and Rhando, 2005; Collins, 2006). Furthermore, Schultz (1996) 
explored the heterogeneous nature of the satellite cell population. Using 
bromodeoxyuridine (BrdU) labelling techniques in rat muscles, the author 
determined that approximately 80% of the population were labelled after five 
 31 
 
days of continuous BrdU infusion, while the remaining 20% represented a more 
slowly dividing subset of cells. The authors therefore suggested that the capacity 
to self-renew could be restricted to a small proportion of the satellite cell 
population, as by limiting mitotic divisions the reserve population of satellite 
cells could conserve their proliferative capacity until required for muscle 
regeneration and repair.  
 
Although none of these theories have been disproved, there is limited 
knowledge of the molecular mechanisms involved in regulating satellite cell 
self-renewal. However, Conboy and Rando (2002) recently investigated the 
regulation of Notch-1 by its antagonist, Numb; specifically looking at its role in 
myogenic cell-fate determination and the activation of satellite cells. The 
authors discovered that injury-induced activation of satellite cells produced a 
heterogeneous population of daughter cells that differed in their levels of Notch-
1 expression. Further studies revealed this coincided with the asymmetric 
distribution of Numb in dividing satellite cells. A link between the level of 
Numb expression and satellite cell fate was therefore proposed, specifically that 
Numb may determine whether a daughter cell becomes committed to the 
myogenic lineage or adopts the quiescent state. However, the levels of Numb 
expression associated with each of these states is yet to be determined.  
 
The myogenic regulatory factors Myf-5 and MyoD are also thought to play a 
role in the regulation of satellite cell self-renewal. As previously mentioned, 
mice deficient in MyoD show a reduced capacity for muscle regeneration. More 
specifically, increased levels of proliferation and reduced levels of  
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Figure 1.3: Mechanisms of satellite cell self-renewal 
 
Satellite cells may undergo self-renewal via the return of an activated daughter cell to the 
quiescent state, or by asymmetric division. Other cell types, such as bone marrow-derived cells, 
may also contribute to the satellite cell population (Collins, 2006).   
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differentiation are associated with the MyoD-null phenotype. It has been 
suggested that an intermediate phase between quiescent satellite cells and 
muscle precursor cells is characterised by this MyoD-deficient phenotype. 
Furthermore, satellite cells are known to express either Myf-5 or MyoD upon 
activation and then co-express the two later; therefore leading to the hypothesis 
that Myf-5+/MyoD- cells represent a population of self-renewing satellite cells 
(Sabourin et al., 1999; Yablonka-Reuveni et al., 1999a; Cornelison et al., 2000; 
Chargé & Rudnicki, 2004).  
 
1.4.2. Contributions of Other Cells 
It is important to understand that although widely accepted, the satellite cell may 
not be solely responsible for skeletal muscle regeneration. Other stem cell 
sources may contribute directly to the quiescent satellite cell pool (Figure 1.3). 
For example, LaBarge and Blau (2002) recently used transplantation studies to 
demonstrate the ability of bone marrow-derived cells to give rise to functional 
muscle satellite cells capable of following a myogenic lineage and participating 
in skeletal muscle regeneration. Side population (SP) cells, which are a muscle-
derived source of stem cells, have also been shown to contribute to skeletal 
muscle regeneration and to the quiescent satellite cell pool. SP cells do not 
display any key satellite cell markers and therefore represent a completely 
separate population of cells. However, myogenic colonies have been produced 
by the co-culturing of SP cells with myoblasts in vitro and SP cells have been 
shown to successfully contribute to the quiescent satellite cell pool following 
their intramuscular transplantation into skeletal muscle (Asakura et al., 2002; 
Holterman & Rudnicki, 2005).  
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1.5. The Inflammatory Response 
In addition to the activation of satellite cells, the onset of the inflammatory 
response is also a key milestone in the highly synchronised sequence of events 
which occurs following muscle injury or increased muscle load. Although one 
of the primary functions of the inflammatory response is to provide a defence 
system against invading pathogens, its role in the tissue repair process, and 
particularly the regulation of wound healing by molecules secreted by the 
various types of immune cells, is of interest to this thesis (Park & Barbul, 2004; 
Tsirogianni et al., 2006).  
 
In the event of muscle injury or increased muscle load, the sarcolemma of 
individual muscle fibres is usually damaged, resulting in various degrees of fibre 
necrosis and an overall disruption of the tendon-myofibre-tendon functional 
unit. The origin of the earliest inflammatory signals is not clear; however current 
evidence suggests that upon injury, the myogenic cells of the damaged muscle 
activate the inflammatory cells located within the muscle, and they in turn 
release substances such as adenosine, ATP and uric acid which act as 
chemoattractants to facilitate the migration of circulating inflammatory cells to 
the site of injury. In addition, the injury stimulates platelet-secretion of several 
growth factors which also aids in this process of inflammatory cell attraction 
(Tidball, 1995; Kääriäinen et al., 2000; Chargé & Rudnicki, 2004; Martin & 
Leibovich, 2005).  Neutrophils are the first of these immune cells to arrive and 
their primary roles are to eradicate microbes from the area. They release 
proteases which aid in the degradation of cellular debris and thereby reduce the 
possibility of infection (Mutsaers et al., 1997; Park & Barbul, 2004; Martin & 
Leibovich, 2005; Tidball, 2005; Tsirogianni et al., 2006). However, it has been 
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suggested that in the process of destroying infectious agents at the injury site, 
neutrophils may also unwittingly damage healthy surrounding tissues through 
the release of high concentrations of cytotoxic and cytolytic molecules, such as 
hydrogen peroxide (Tiidus, 1998; Martin & Leibovich, 2005; Tidball, 2005; 
Butterfield et al., 2006).  
 
Soon after the infiltration of neutrophils, tissue monocytes migrate to the wound 
site and differentiate into mature macrophages between 48 and 96 hours after 
injury (DiPietro, 1995; Park & Barbul, 2004). Macrophages are rapaciously 
phagocytic, removing any neutrophils from the wound area which have already 
undergone apoptosis, in addition to extracellular matrix and cellular debris 
(Martin & Leibovich, 2005).  Founding studies carried out by Simpson and Ross 
(1972) and Leibovich and Ross (1975), which were later supported by Dovi et 
al. (2003), demonstrated the impaired ability of wounded guinea pigs to clear 
cellular debris after the administration of antimacrophage serum and steroids; as 
these compounds removed all circulating monocytes and tissue macrophages 
from the animals. Interestingly, when this study was repeated in guinea pigs 
depleted of neutrophils instead of macrophages, no adverse effects on tissue 
repair were observed. This led the authors to conclude that, unlike neutrophils, 
macrophages are essential for normal wound healing (Martin & Leibovich, 
2005). Furthermore, Dovi et al. (2003) suggested that since neutrophils were not 
fundamental to the injury repair process, any chemokines released by these cells 
were thus redundant to wound healing, meaning other cells could produce large 
quantities of the same substances or some viable alternative.  
 
 36 
 
In addition to their phagocytic abilities, macrophages also secrete various 
cytokines and growth factors which contribute to the regulation of wound 
healing. Examples of some of these substances include IGF-1, IL-1 and IL-6, 
leukemia inhibitory factor (LIF), platelet-derived growth factor (PDGF), TGF-
alpha (TGF-) and TGF-, and tumor necrosis factor-alpha (TNF-). These 
substances recruit other cells involved in wound repair, such as endothelial cells, 
and regulate fibroblast chemotaxis, proliferation and collagen synthesis. 
Therefore, macrophages play a key role in the formation of new blood vessels, 
fibrous tissue and matrix synthesis during wound repair (DiPietro, 1995; 
Mutsaers et al, 1997; Park & Barbul, 2004). Furthermore, macrophages express 
inducible nitric oxide synthase (iNOS), which has been shown to mediate 
wound closure and collagen deposition (DiPietro, 1995; Mutsaers et al, 1997; 
Park & Barbul, 2004).  
 
Macrophage-released factors are also thought to be directly involved in the 
regulation of satellite cells. Lescaudron et al. (1993; 1997) discovered that the 
stimulation of macrophage infiltration in a transplantation model led to earlier 
activation of satellite cells. Furthermore, an increased proportion of MyoD-
positive nuclei (a molecular marker for satellite cell proliferation) was observed 
in satellite cells co-cultured with macrophages. Of the plethora of substances 
released by macrophages, it was LIF and TNF- which appeared to be 
responsible for stimulating proliferation of the satellite cells (Kurek et al., 1996; 
Merly et al., 1999). 
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1.6. Myostatin 
The TGF- superfamily is comprised of a diverse range of growth and 
differentiation factors that are involved in regulating both pre-natal and post-
natal myogenesis.  One of the key members of this group is myostatin, also 
known as growth and differentiation factor-8 (GDF-8), which is expressed in 
embryonic and adult skeletal muscle. Myostatin has been identified as a potent 
negative regulator of muscle growth (McPherron et al., 1997; Thomas et al., 
2000).  
 
1.6.1. Myostatin Structure and Expression 
Myostatin shares a number of common features with the other members of the 
TGF- superfamily. These include a secretory signal sequence consisting of a 
hydrophobic core of amino acids located near the N-terminus, a proteolytic 
processing site, and a conserved pattern of nine cysteine residues, which forms a 
distinguishing cystine knot structure at the C-terminus (Thomas et al., 2000; 
Jeanplong et al., 2001; Langley et al., 2002; Kambadur et al., 2004; Zhu et al., 
2004). More specifically, Vitt et al. (2001) described how the presence of 
cysteine residues in amino acid chains is fundamental for disulfide bonding and 
loop formation, in order to generate a functional protein motif. Crystal structures 
have revealed that of the nine cysteine residues characteristic of TGF- 
superfamily members, eight of them form four intrachain disulphide bonds 
which further conform into intertwining loops that create the knot structure, 
while the ninth cysteine residue forms an interchain disulfide bond which 
confers stability (Daopin et al., 1992; Sun, 1995). The cystine knot structure 
directs the three-dimensional arrangement adopted by the protein, which 
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subsequently exposes hydrophobic residues involved with the formation of 
homo- or heterodimers required for biological activity.  
 
The myostatin gene itself is organised into three exons and two introns, and is 
translated as a full-length peptide that is synthesised in skeletal muscle in its 
precursor form, a 375 amino acid propeptide. The biologically active molecule 
is generated following two proteolytic processing events; the initial removal of 
the 24 amino acid signal peptide which is involved with the secretory pathway, 
and cleavage at the RSRR (Arg-Ser-Arg-Arg) site to produce a 39 kDa N-
terminal Latency Associated Protein (LAP), and a 26 kDa carboxyl-terminal (C-
terminal) mature myostatin molecule (Figure 1.4) (Thomas et al., 2000; 
Kambadur et al., 2004; Lee, 2004).  
 
The myostatin sequence is highly conserved, with murine, rat, human, porcine, 
chicken and turkey species showing 100% homology of the active, 
proteolytically processed site; while baboon, bovine and ovine mature myostatin 
proteins differ only in one to three amino acids (McPherron & Lee, 1997; 
Kocamis & Killefer, 2002).  
 
Expression of myostatin mRNA is first detected at day 9.5 post-coitum in 
approximately one third of mouse somites, specifically the most mature rostrally 
located ones.  By day 10.5 post-coitum it is expressed in nearly every somite 
and appears to be limited to the myotome compartment. After further 
development, myostatin expression can be detected in the majority of 
developing muscles (McPherron et al., 1997; Kocamis & Killefer, 2002; Bishop 
et al., 2005). Myostatin expression in muscle appears to be fibre-type specific.  
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Figure 1.4: The structure of myostatin 
 
A) The biologically active myostatin molecule is generated following two proteolytic processing 
events; the removal of the amino acid signal peptide, and cleavage at the RSRR site. B) After 
proteolytic processing, the C-terminal dimer remains noncovalently bound to the LAP, forming 
a latent complex. C) Proteolytic cleavage of LAP activates the latent myostatin D) The C-
terminal dimer is released and thus capable of receptor binding. Adapted from Lee (2004). 
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The different types of skeletal muscle fibres can be characterised by different 
myosin heavy chain (MHC) isoforms (Linnane et al., 1999), and a strong 
correlation exists between myostatin expression and MHC type-IIb expression, 
which is associated with fast muscle fibres (Carlson et al., 1999; Senna Salerno 
et al., 2004; Bishop et al., 2005).  Although myostatin is predominantly 
expressed in skeletal muscle tissue, it has also been detected at low levels in 
adipose tissue (McPherron et al., 1997), lactating mammary gland tissue (Ji et 
al., 1998), and in the cardiomyocytes and Purkinje fibres of the heart (Sharma et 
al., 1999).   
 
1.6.2. Myostatin Signalling Pathways  
Members of the TGF- superfamily are secreted growth factors; therefore in 
order to elicit their biological effect they first need to bind to a receptor which 
subsequently activates a signal transduction cascade in the target cell 
(Kambadur et al., 2004; Lee, 2004). Lee and McPherron (2001) suggested that 
following proteolytic processing, the myostatin C-terminal dimer remains 
noncovalently bound to the LAP, forming a latent complex. Activation of latent 
myostatin occurs through the proteolytic cleavage of LAP at the RSRR site 
(Figure 1.4), after which the C-terminal dimer is capable of binding to its 
receptor, activin type IIB (Act RIIB). In addition, it can also bind Act RIIA, but 
to a lesser extent. Based on the signalling mechanisms of other TGF- related 
ligands, the type-II receptor kinase is then thought to phosphorylate the recruited 
type-I receptor kinase, activin receptor-like kinase 5 (Alk5), which in turn 
phosphorylates the Smad proteins (Kambadur et al., 2004; Lee, 2004). The 
Smad proteins translocate to the nucleus and function as intracellular signal 
transducers to regulate the expression of downstream genes (Padgett et al., 1998; 
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Roberts, 1999; Lee, 2004; Zhu et al., 2004; Bishop et al., 2005). In particular, 
Zhu et al. (2004) identified Smad2, Smad3 and Smad4 as key molecules in 
myostatin signal transduction while Smad7 mediates a negative feedback 
mechanism involved in regulating myostatin signalling (Forbes et al., 2006).  
 
1.6.3. The Function of Myostatin 
1.6.3.1. Inactivation of Myostatin 
As previously mentioned, myostatin has been identified as a potent negative 
regulator of muscle mass. McPherron et al. (1997) used gene targeting 
techniques to disrupt the myostatin gene in mice and reported that myostatin-
null animals were significantly larger in size than their wild-type counterparts 
(Figure 1.5A). This increase in skeletal muscle mass was due to a combination 
of both hyperplasia (an increase in the number of muscle fibres) and 
hypertrophy (an increase in individual fibre diameter). The hypermuscularity 
observed in some cattle breeds, such as the Belgian Blue (Figure 1.5D) and 
Piedmontese has also been investigated. These breeds are defined by a double 
muscle phenotype which results in a 15 to 30% increase in muscle mass, but this 
is accompanied by birthing difficulties and other problems such as low stress 
tolerance and decreased female fertility (Potts et al., 2003).  
 
The double-muscle phenotype was found to be the result of naturally occurring 
mutations which inactivate the myostatin gene (Grobet et al., 1997; Kambadur et 
al., 1997; McPherron & Lee, 1997). More specifically, an 11 base-pair (bp) 
deletion was found in the myostatin gene of Belgian Blue animals and this led to 
a frame-shift mutation resulting in premature translational termination of 
mysotatin. In contrast, a guanine to adenine transition in the myostatin gene was 
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found to be responsible for Piedmontese hypermuscularity. This caused a 
cysteine residue to be substituted for a tyrosine, ultimately disrupting the 
important cystine knot structure of the myostatin molecule, inactivating it 
(Kambadur et al., 1997; Berry et al., 2002). Recently, Shelton and Engvall 
(2007) also reported a myostatin mutation in a whippet dog displaying gross 
muscle hypertrophy (Figure 1.5C); and a human child with the heavy muscle 
phenotype has been found to carry a mutation in the myostatin gene, thought to 
be generated by the mis-splicing of myostatin precursor mRNA (Figure 1.5B) 
(Schuelke et al., 2004; Walsh & Celeste, 2005). 
 
1.6.3.2. Mechanism of Myostatin Action 
Numerous studies have suggested that myostatin functions by regulating 
myoblast proliferation and differentiation during early myogenesis (Thomas et 
al., 2000; Langley et al., 2002), followed by the control of satellite cell 
activation post-natally (McCroskery et al., 2003). Thomas et al. (2000) 
demonstrated a dose-dependent relationship between increasing levels of 
myostatin and decreasing levels of C2C12 mouse myoblast proliferation. More 
specifically, myostatin was revealed to inhibit the progression of myoblasts from 
the G1 to S phase of the cell cycle. The authors proposed that myostatin 
signalling mediated this effect through an increase in the expression of p21, a 
CDK inhibitor. This was accompanied by decreased levels and activity of CDK2 
protein, the principal cyclin-dependent kinase responsible for cell-cycle 
progression from the G1 to S phase. As a result, retinoblastoma (Rb) proteins 
accumulated, leading to myoblasts being detained at the G1 phase, and therefore 
inhibiting proliferation (Figure 1.6) (Langley et al., 2004).  
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Figure 1.5: Inactivation of myostatin results in double-muscling phenotypes  
 
A) Myostatin-null mice (bottom) show an increase in skeletal muscle mass compared to wild-
type mice (top) (McPherron et al., 1997). B) Muscle hypertrophy in a human neonate (left) and 
at 7 months old (right), as a result of a myostatin mutation (Schuelke et al., 2004). C)  A double 
muscled whippet dog (left) carries a homozygous mutation in the myostatin gene which is not 
present in wild-type animals (right) (Shelton and Engvall, 2007). D) A Belgian Blue bull 
showing the double muscle phenotype (McPherron and Lee, 1997). 
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Figure 1.6: Mechanisms of myostatin action 
 
Myostatin regulates myoblast proliferation and differentiation to myotubes through the control 
of cell-cycle progression. Increased levels of p21 and decreased levels of Cdk2 expression result 
in accumulated Rb protein which prevents entry into the G1 phase of the cell cycle. Likewise, 
myostatin signalling through Smad3 results in the decreased expression of myogenin and MyoD, 
therefore inhibiting myoblast differentiation (Langley et al., 2002).  
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In regard to the regulation of myoblast differentiation, Langley et al. (2004) 
recently demonstrated that when myoblasts were cultured in low serum media 
with increasing concentrations of myostatin, myogenic differentiation of the 
myoblasts was reversibly blocked. The authors determined that expression of the 
myogenic regulatory factors MyoD, Myf-5 and myogenin, along with p21, were 
significantly decreased in the presence of myostatin, thereby inhibiting myoblast 
differentiation (Figure 1.6). These results support the findings of Rios et al. 
(2002) and Joulia et al. (2003), who studied the effects of myostatin 
overexpression on stably transfected C2C12 myoblasts, drawing similar 
conclusions.  
 
In addition to the expression of myostatin in skeletal muscle fibres, myostatin 
has also been detected specifically in satellite cells, indicating a role in muscle 
 regeneration and repair (McCroskery et al., 2003; Bishop et al., 2005).  
McCroskery et al. (2003) reported a significantly higher number of satellite cells 
per skeletal muscle fibre in myostatin-null mice compared to their wild-type 
counterparts; and a greater proportion of these cells were in an activated state. 
The authors suggested that, similar to the regulation of myoblast proliferation 
and differentiation, myostatin inhibits cell cycle progression, thereby 
maintaining satellite cells in a quiescent state. Furthermore, myoblasts isolated 
from myostatin-null mice were found to proliferate faster than wild-type 
myoblasts, implying that myostatin may also negatively regulate satellite cell 
self-renewal.  
 
The intrinsic mechanisms involved in satellite cell regulation by myostatin are 
yet to be fully elucidated however, McFarlane et al. (2008) recently proposed a 
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model whereby myostatin negatively regulates the expression of the 
transcription factor Pax7, which in turn regulates satellite cell self-renewal. Pax7 
is widely expressed in quiescent satellite cells, is co-expressed with MyoD 
during satellite cell proliferation, and is then down-regulated prior to 
differentiation. Pax7-null mice show a reduced capacity for regeneration, with a 
gradual decrease in satellite cell numbers as a result of cell cycle defects and 
increased levels of apoptosis (Kuang et al., 2006; Relaix et al., 2006; McFarlane 
et al., 2008). 
 
1.6.4. Therapeutic Potential of Myostatin Antagonists 
The establishment of myostatin as a potent negative regulator of muscle mass, 
muscle regeneration and muscle repair, has enabled the concept of myostatin 
antagonists to emerge in the realm of pharmacological therapies. More 
specifically, the ability to block myostatin function has enormous potential in 
the treatment of muscle injuries and the many muscle wasting conditions 
associated with age or disease. The Functional Muscle Genomics (FMG) group 
at AgResearch Ltd. have recently developed several myostatin antagonists by 
truncating the biologically active mature myostatin sequence, as shown in 
Figure 1.7. 
 
Siriett et al. (2007) recently tested the myostatin antagonist, Mstn-ant1. Using a 
notexin injury model, the authors reported enhanced regeneration levels in 
Mstn-ant1 treated mice, facilitated through the earlier and increased response of 
macrophages, and the increased activation and migration of satellite cells, when 
compared to placebo-treated mice. These results support the findings of  
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Figure 1.7:  Myostatin antagonist truncations 
The FMG group at AgResearch Ltd. have developed several myostatin antagonists by truncating 
the active mature myostatin sequence (processed myostatin) at different amino acid sites. 
Specifically, Mstn-ant1 was truncated at amino acid 350, Mstn-ant3 at amino acid 300, Mstn-
ant4 at amino acid 310 and Mstn-ant5 at amino acid 320. Each antagonist varies in the number 
of cysteine (C) residues it contains. 
 
 48 
 
McCroskery et al. (2005), who observed a similar response in notexin injured 
myostatin-null mice. Furthermore, both McCroskery et al. (2005) and Siriett et 
al. (2007) reported reduced levels of scarring after injury in the myostatin-null 
animals and wild-type mice treated with Mstn-ant1 respectively. Scarring is a 
by-product of the inflammatory response and subsequent stages of wound 
healing. Fibroblasts are attracted to the wound area via chemotactic signals 
released from the invading macrophages. They secrete growth factors and 
various extracellular matrix proteins, such as collagen, which aid in the repair of 
wounded tissue. Unfortunately, excessive amounts of fibrotic tissue are usually 
produced, forming a physical barrier which hinders skeletal muscle 
regeneration, resulting in scarring (Zhu et al., 2007; Li et al., 2008). Recent in 
vitro and in vivo studies carried out by Li et al. (2008), have revealed that 
myostatin directly regulates skeletal muscle fibrosis through the stimulation of 
both fibroblast proliferation and the production of extracellular matrix proteins.  
 
The use of myostatin antagonists in the treatment of sarcopenia has also been 
investigated. Sarcopenia is the gradual loss of skeletal muscle mass and strength 
commonly associated with ageing. It is facilitated through impaired satellite cell 
function and myogenesis, leading to reduced levels of muscle regeneration. 
Recently, sarcopenia has been linked to myostatin, with studies showing a 
significant reduction in sarcopenia in myostatin-null mice (Siriett et al., 2006; 
2007).  Siriett et al. (2007) further studied the effects of short-term myostatin 
blockade on sarcopenia, using Mstn-ant1. The authors reported significantly 
increased levels of myogenesis after notexin injury in aged mice treated with 
Mstn-ant1, when compared to placebo-treated mice. In addition, grip strength 
measurements indicated that the administration of Mstn-ant1 significantly 
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increased the muscle strength of aged mice. Again, an earlier and increased 
response of macrophages and increased activation and migration of satellite 
cells was observed in the aged mice treated with Mst-ant1 following notexin 
injury.  
 
An alternative myostatin antagonist, Mstn-ant3, is truncated at a different 
location to Mstn-ant1, and has been shown to attenuate muscle wasting in mdx 
mice (Kambadur et al., 2006c). This mouse model is representative of Duchenne 
and Becker muscular dystrophies, a chronic myopathy resulting in repeated 
rounds of muscle degeneration followed by incomplete regeneration, and 
ultimately leads to widespread fibrosis (Wagner et al., 2002). Mdx mice treated 
with Mstn-ant3 showed an overall improvement in dystrophic muscle 
morphology, with reduced areas of necrosis and increased regeneration. In 
addition, treatment of mdx mice with Mstn-ant3 led to decreased levels of 
creatine kinase (CK), a serum marker of muscle damage and breakdown, usually 
found at high levels in mdx mice. Grip strength measurements also indicated a 
significant improvement in the strength of dystrophic muscles over the treatment 
period (Kambadur et al., 2006c). These results reflect those of Bogdanovich et 
al. (2002) and Wagner et al. (2002) who studied the effect of myostatin-blocking 
antibodies on dystrophic muscles, and dystrophic muscle in myostatin-null mdx 
mice, respectively.  
 
Studies have also been carried out on the role of myostatin in cachexia, a severe 
muscle wasting condition seen in many cancer and AIDS patients. Zimmers et 
al. (2002) demonstrated that systemic administration of myostatin protein in 
mice produced a muscle and fat-loss phenotype which paralleled that seen in 
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human cachexia conditions. It was recently suggested that the mechanism 
behind this myostatin-induced cachexia was the activation of the ubiquitin-
proteasome pathway, via the regulation of the transcription factor FoxO1 by 
myostatin (McFarlane et al., 2006). The administration of the glucocorticoid 
Dexamethasone (Dex) in mice is a widely accepted laboratory model for 
cachexia. Ma et al. (2003) reported a significant upregulation in myostatin 
expression during glucocorticoid-induced muscle atrophy, while Gilson et al. 
(2007) demonstrated that absence of myostatin could prevent this atrophy. 
Studies have shown that the expression of Pax7 and MyoD was significantly 
decreased in mice treated with Dex; however this was reversed with the 
administration of Mstn-ant3 (unpublished data). These results suggest a 
potential role for myostatin antagonists in the alleviation of cachexia symptoms.  
 
The actual mechanism of action for the myostatin antagonists is yet to be fully 
defined. However, it is thought that the antagonist may either form a 
heterodimer with endogenous myostatin, leading to the impaired ability of the 
heterodimer to signal through the Act RIIB receptor; or that the antagonist may 
directly bind to the receptor and therefore play a role in competitive binding 
(personal communication).   
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1.7. Objectives and Hypotheses 
Myostatin has been identified as a potent negative regulator of muscle mass and 
functions by regulating myoblast proliferation and differentiation during early 
myogenesis; followed by the post-natal control of satellite cell activation 
(Thomas et al., 2000; Langley et al., 2002). In addition, myostatin is thought to 
inhibit muscle regeneration and repair (McCroskery et al., 2003). Therefore, the 
ability to block myostatin function has significant potential in the treatment of 
muscle injury and various muscle wasting conditions associated with age and 
disease. This concept has been supported by numerous studies carried out using 
myostatin-null mice, murine models of wound healing, such as notexin and 
incision injury, and murine models of muscle wasting, such as sarcopenia, mdx 
and glucocorticoid-induced cachexia (Bogdanovich et al., 2002; Zimmers et al., 
2002; Wagner et al., 2002; Ma et al., 2003; McCroskery et al., 2005; Siriett et 
al., 2006; Gilson et al., 2007; Siriett et al., 2007; unpublished data). In addition, 
the recent development of myostatin antagonists has been a significant 
advancement in this field of study (Kambadur et al., 2006a; 2006b; 2006c; 
Siriett et al., 2007). 
 
1.7.1. Development of the Muscle Burn Injury Model 
Although various murine muscle injury models exist, there is currently no 
standardised murine muscle burn injury model. Therefore, a significant 
proportion of time and research for this thesis was dedicated to developing and 
testing the first murine muscle burn injury that could be utilised for both this 
thesis and future wound healing studies. When combined with existing injury 
models, the murine burn injury model enables a more accurate representation of 
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muscle wound healing, which is important for the development of 
pharmaceutical therapies that will aid in the wound healing process.  
 
To develop this burn injury model, numerous different thermal injury techniques 
that have previously been developed and published were first reviewed. The 
severity of the burn wound produced by each technique ranged from partial-
thickness to full-thickness (determined by the degree of damage to the 
epidermis, dermis and associated nerve endings) and from 3% to 40% total body 
surface area. Furthermore, a variety of animal species were used in the 
development of these burn injury models, including mice, rats, sheep and pigs.   
 
Briefly, Stieritz and Holder (1975) originally isolated an area of shaved skin on 
the back of a mouse using a flame-resistant plastic card with a window in it. 
Ethanol was applied to the open area, ignited and allowed to burn for 10 s 
(Neely et al., 1999, Higashimori et al., 2005). These template devices have also 
been used with other burn agents, such as exposing the skin area in the window 
to 100ºC temperature water (Pawlik et al., 2003; Ballard-Croft et al., 2004). 
Gore et al. (2005) also explored the use of a Bunsen burner flame to produce a 
severe burn injury on the back and flanks of mice. This method was also used to 
produce a flame burn wound in sheep (Sakurai et al., 2002). Bairy et al. (1997) 
used an alternative approach, placing a metal cylinder on the back of a rat and 
pouring hot molten wax at a temperature of 80ºC down it. The cylinder was 
removed once the wax had solidified (approximately 8 min), leaving a 
consistent circular wound. Astrakas et al. (2005) and Padfield et al. (2005) 
described a less severe method, where the left hind limb of an anaesthetised 
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mouse was immersed in 90ºC water for 3 s, producing a scald injury that was 
only 3-5% of the total body surface area.   
 
Other instruments have also been constructed to produce burn injuries. Most 
popular are brass bars, which are heated in 100ºC boiling water before being 
applied to the skin (Meyer & da Silva, 1999; Willis et al., 2005; Møller-
Kristensen, et al., 2006; Møller-Kristensen, et al., 2007). Alternatively, brass 
plates heated in 100ºC boiling water were used to produce burn injuries on the 
sides of larger animals such as pigs (Papp et al., 2005). The use of lasers has 
also been explored, with the aim of producing burns of a consistent depth to 
reduce variability (Cohen et al., 2003). With regard to a thermal burn injury 
specifically to skeletal muscle, there appears to be only one entry in the 
literature. Toader-Radu (1978) passed a red-hot metallic needle through the skin 
of the hind limb of rats, and applied it to the surface of the TA muscle. 
However, this produced only a small burn area, lacking consistency in its 
severity.   
  
For the purpose of developing a murine muscle burn injury model for this thesis, 
the methods outlined above were discussed with the Ruakura Animal Ethics 
Committee. Those involving the use of ignited ethanol and a Bunsen burner 
flame were not approved and some of the other techniques were not physically 
appropriate to use on skeletal muscle. In addition, some burn injury techniques 
had a higher risk of infection, which needed to be avoided.   
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1.7.2. In vivo Trial 
In addition to developing a murine muscle burn injury model, this thesis 
describes the first in vivo trial using the myostatin antagonist, Mstn-ant4. 
Specifically, the ability of Mstn-ant4 to improve wound healing was evaluated 
using the murine muscle burn injury model. Results from this thesis contributed 
to a larger study being undertaken by the FMG group at AgResearch Ltd., with 
the aim of determining the efficacy of myostatin antagonists on different muscle 
regeneration conditions.  
 
Three key techniques were used to analyse the results of the in vivo trial: 
histology, gene expression analysis using RNA, and immunocytochemistry.  
 
The histological analysis focused on two established staining techniques, 
Haematoxylin and Eosin (H and E) and Van Geison. One of the characteristic 
features of skeletal muscle regeneration is the presence of centrally formed 
nuclei (CFN) in the muscle fibres (Brazelton et al., 2003), which can be detected 
using H and E staining. Following the burn injury, extensive skeletal muscle 
regeneration would be expected to occur and therefore an associated increase in 
CFN would be hypothesised. Van Gieson staining detects collagen deposition in 
a tissue. As discussed in Section 1.6.4 of this thesis, scarring forms as a result of 
excessive fibrotic tissue being produced during the inflammatory response and 
subsequent stages of wound healing. A key component of fibrotic tissue is 
collagen, and therefore Van Gieson staining can be used as an indicator for the 
level of fibrogenesis occurring in a tissue. Similar to CFN, an increase in the 
levels of collagen deposition over time would be expected as muscle 
regeneration progresses following the burn injury.  
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There are actually five different types of collagen present in adult skeletal 
muscle: types I, III, IV, V and VI (Listrat et al., 1999). Collagen types I and III 
are the most abundant of these and they each have specific localisations. 
Collagen type I is predominantly found in tendons and the epimysium, but can 
also appear in small quantities in the perimysium, while collagen type III is 
predominantly found in the perimysium (Duance et al., 1977). Methods 
including Semi-Quantitative PCR and Real-Time PCR use RNA to analyse the 
expression level of targeted genes in a specified tissue, and therefore these 
techniques were used to evaluate the gene expression levels of collagen types I 
and III for this thesis. An increase in both collagen types I and III gene 
expression would be expected to reflect the results of the Van Gieson staining. 
Furthermore, Garcia-Filipe et al. (2006) recently described a ‘fibrotic index’ 
used to evaluate the levels of fibrogenesis during wound healing following a 
skin burn injury. Specifically, the authors evaluated the ratio of collagen type III 
to collagen type I production and suggested that a relative increase in collagen 
type III could be indicative of extensive fibrosis.  
 
In addition to collagen, the expression levels of four myogenic genes were also 
evaluated for this thesis; namely mighty, MyoD, myogenin and Pax7. Mighty, a 
downstream target of myostatin, is a novel gene that was discovered by the 
FMG group at AgResearch Ltd. during studies investigating the mechanisms by 
which myostatin negatively regulates muscle mass. Mighty was found to play a 
key role in the enhanced differentiation and hypertrophy of myoblasts, 
characteristic of reduced levels of myostatin expression (Marshall et al., 2008). 
Therefore, analysing mighty expression is a useful tool for evaluating the levels 
of myogenesis occurring in skeletal muscle. Previous analyses of mighty 
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expression in notexin and incision injury models (Senna Salerno et al., 
submitted) show mighty expression is first detectable at day 2 post-injury, 
followed by a peak in expression levels between days 5 and 7 post-injury, before 
a gradual decline in expression. For this thesis, a similar pattern of mighty gene 
expression would be expected following the burn injury.   
 
As discussed in Section 1.3.3.1, MyoD and myogenin are MRFs that are 
essential for the growth of muscle during skeletal muscle development. More 
specifically, MyoD is involved with regulating the determination process, 
leading to the multipotent somite cells being committed to the myogenic 
lineage, while myogenin is involved with the initiation of myoblast 
differentiation which occurs later in the myogenic programme. Therefore the 
analysis of MyoD and myogenin expression are useful for evaluating the levels 
of myogenesis occurring in skeletal muscle, and we would expect MyoD 
expression to be upregulated earlier than myogenin expression, following the 
burn injury.  
 
Section 1.4.1 of this thesis discussed the capacity of satellite cells to facilitate 
the majority of post-natal skeletal muscle growth, maintenance, repair and 
regeneration. Upon activation from the quiescent state, satellite cells co-express 
Pax7 and MyoD while they proliferate, and then down-regulate Pax7 prior to 
differentiation. In addition, to prevent depletion of the satellite cell pool, 
evidence suggests that satellite cells have the ability to self-renew, and Pax7 has 
been implicated in the regulation of this process (Kuang et al., 2006; Relaix et 
al., 2006; McFarlane et al., 2008). Recent studies have shown that myostatin 
negatively regulates the expression of Pax7 (McFarlane et al., 2008). Therefore, 
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analysing Pax7 expression can be a useful tool for monitoring regeneration via 
satellite cells in skeletal muscle. An increase in Pax7 gene expression would be 
expected following the burn injury; due to more satellite cells being activated to 
participate in muscle regeneration and also to undergo self-renewal in order to 
replenish the satellite cell pool that would have subsequently been depleted.  
 
Finally, a key event of the inflammatory response is the infiltration of 
macrophages to the wound site and this was evaluated for this thesis using 
Macrophage antigen complex-1 (Mac1) immunocytochemistry (ICC). As 
discussed in Section 1.5, macrophages are rapaciously phagocytic, removing all 
cellular debris in preparation for fibre repair and new fibre formation. As a 
member of the leukocyte-specific beta (2) integrin family, Mac1 is involved 
with all aspects of the inflammatory response, including phagocytosis, 
chemotaxis, migration and adhesion (Mayadas & Cullere, 2005; Hu et al., 
2008). In addition, evidence suggests that Mac1 plays a key role in inducing the 
NF-B transcription factor signalling pathway, which leads to the production of 
inflammatory factors (Ingalls et al., 1998; Medvedev et al., 1998; Hu et al., 
2008). Therefore one would expect the infiltration of macrophages to the site of 
burn injury to be quite substantial soon after the burn injury is inflicted to clear 
the area, and then gradually decline as skeletal muscle regeneration progresses. 
 
1.7.3. Hypotheses 
Overall, based on the results of previous studies using myostatin-null mice, 
murine models of muscle wound healing such as notexin and incision injury, 
and murine models of muscle wasting, such as sarcopenia, mdx and cachexia 
(Bogdanovich et al., 2002; Zimmers et al., 2002; Wagner et al., 2002; Ma et al., 
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2003; McCroskery et al., 2005; Siriett et al., 2006; Gilson et al., 2007; Siriett et 
al., 2007; unpublished data), as well as those using other myostatin antagonists 
(Kambadur et al., 2006a; 2006b; 2006c; Siriett et al., 2007); it can be 
hypothesised that following a burn injury in mice, the administration of Mstn-
ant4 would significantly improve wound healing compared to placebo-treated 
mice. Specifically, the levels of CFN and the number of CFN per fibre would be 
expected to be higher in the Mstn-ant4-treated mice, as well as higher 
expression levels of the myogenic genes and an increased and earlier migration 
of macrophages to the site of injury. On the other hand, collagen deposition 
detected by Van Geison staining, as well as the gene expression levels of 
collagen types I and III would be expected to be lower in mice treated with 
Mstn-ant4 compared to placebo-treated mice.  
 
1.7.4. Objectives 
The specific objectives for this thesis are as follows: 
 
Objective 1: To develop a murine muscle burn injury model suitable for using in 
both this thesis and future wound healing studies.  
 
Objective 2: To determine the efficacy of Myostatin-antagonist4 on wound 
healing following a severe muscle burn injury.  
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Chapter Two: Materials and Methods 
 
 
2.1. Materials 
2.1.1. Animals 
Ten male mice of the wild-type strain C57 bl/6 were used for a pilot trial. These 
mice were approximately 12 months of age. A further 96 male mice of the wild-
type strain C57bl/6 were used in the main in vivo trial. These mice were 
approximately 9 months of age. All animals were bred and housed at the 
Ruakura Small Animal Colony containment facility, and kept at a constant 
temperature of 20-22ºC, with a natural day/night cycle, and food and water 
available ad libitum. Approval from both the Ruakura Animal Ethics Committee 
and The University of Waikato Animal Ethics Committee was granted prior to 
any animal manipulations were carried out.  
 
2.1.2. Oligonucleotide Primers  
Oligonucleotide primers were designed for use in the Semi-Quantitative 
Polymerase Chain Reaction (PCR) and Real-Time PCR amplifications of 
cDNA, and were obtained from either Invitrogen or Sigma Aldrich. The 
oligonucleotides were initially re-suspended in 100 µl of MilliQ sterile water 
and stored at -20ºC, before being further diluted with MilliQ sterile water to a 10 
µM working solution for use in PCR. All diluted primer aliquots were stored at  
-20ºC. The primer sequences used in this thesis are listed in Table 1. 
 
2.1.3. Antibodies 
Antibodies used for ICC in this thesis are listed in Table 2.  
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Table 1: Oligonucleotide Primers  
Gene Primer Sequence (5’ to 3’) Product  Size (bp)  Use 
Collagen 
(Type I) 
Fwd: ATGTCGCTATCCAGCTGACC 
Rev:  AAGGGTGCTGTAGGTGAAGC 
 
192 RT 
Collagen 
(Type III) 
Fwd: ATAAGCCCTGATGGTTCTCG 
Rev:  CTTACGTGGGACAGTCATGG 
 
195 RT 
Mighty Fwd: TGAAGCGGCCCATGGAGTTC 
Rev:  GGTGGGCTGGTCCTTCTTCA 
 
350 SQ 
Mighty Fwd: GATGAAGAAGGACCAGCCCAC 
Rev:  TTGGCCTTGTCCCGTATCGC 
 
217 RT 
MyoD Fwd: CGGCGGCAGAATGGCTACGA 
Rev:  TGCAGTCGATCTCTCAAAGCACC 
 
313 SQ &   
RT 
Myogenin Fwd: GAAAGTGAATGAGGCCTTCG 
Rev:  AGATTGTGGGCGTCTGTAGG 
 
308 SQ &  
RT 
Pax7 Fwd: GCTGCCGGACTCTACCTACC 
Rev:  CCAGCACAGCGGAGTGTTCC 
 
571 SQ 
Pax7 Fwd: ACAGCATCGACGGCATCCTG 
Rev:  GTTACTGAACCAGACCTGCACG 
 
272 RT 
18S (HK)  Fwd: AACGTCTGCCCTATCAACT 
Rev:  AACCTCCGACTTTGCTTCT 
 
699 SQ 
H3.3A 
(HK)      
Fwd: GGCTCGTACAAAGCAGACTGCC 
Rev:  GCAATTTCTCGCACCAGACG 
225 RT 
*HK = Housekeeping Gene       *RT = Real-Time       *SQ = Semi-Quantitative 
 
Table 2: Antibodies  
Antibody Dilution  Source 
Rabbit anti-Mighty peptide  1:100 AgResearch 
Goat anti-Mac1 1:100 Santa Cruz 
Biotinylated Donkey anti-Rabbit Ig 1:300 Amersham 
Biotinylated Donkey anti-Sheep/Goat 1:300 Amersham 
Alexa Fluor 488 1:400 Molecular Probes 
DAPI 1:1000 Molecular Probes 
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2.1.4. Solutions 
Common solutions used in this thesis were made according to Ausubel et al. 
(1987) and/or Lillie (1965) and are listed in the Appendix. 
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2.2. Methods 
2.2.1. Pilot Trial  
 A pilot trial was undertaken to determine the conditions for the main in vivo 
trial, including duration and frequency of sample collection. Unfortunately, 
Orico Ltd., who was funding the Enterprise Scholarship for this research, had 
not decided which myostatin antagonist to focus on as a lead molecule at this 
stage, therefore, no antagonist could be tested in conjunction with the burn 
injury during the pilot trial. Based on animal availability at the time, C57bl/6 
mice that were approximately 12 months of age were used.  
 
2.2.1.1. Burn Injury 
Mice were anaesthetised using the general anaesthetic ketamine hydrochloride 
(Class 2) xylazine hydrochloride (Class 2). An incision was made over the left 
TA muscle of the hind limb, and a red-hot metal rod 1.5 mm wide and 7 mm 
long was applied directly to the TA muscle for 5 s. The wound was closed with 
a surgical clip.  
 
2.2.1.2. Sample Collection 
Mice were allowed to heal for 5, 7, 14, 21, and 28 days post-injury. On each of 
these days two mice were sacrificed. The TA muscles were excised and 
processed for histological analysis by coating with Tissue Tek O.C.T compound 
(Sakura) and freezing in liquid nitrogen-cooled iso-pentane (BDH) for 10 s. 
Frozen TA muscles were stored at -80ºC until use. 
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2.2.2. In vivo Trial 
Upon the successful completion of the pilot trial, the in vivo trial commenced. 
By this time, Orico Ltd. had decided to focus on the myostatin antagonist 
truncated at amino acid 310, termed Mstn-ant4, as a lead molecule so this was 
used for the in vivo trial. Ninety-six male mice of the wild-type strain C57bl/6 
were used.  
 
2.2.2.1. Production of Mstn-ant4 
The myostatin antagonist used in this thesis was generated and purified by 
members of the FMG group at AgResearch Ltd. as described by Siriett et al. 
(2007). However, instead of being truncated at the amino acid 350, the 
biologically active mature myostatin sequence was truncated at amino acid 310. 
Briefly, a portion of bovine myostatin cDNA truncated at amino acid 310 was 
PCR-amplified and inserted into the cloning vector pET 16-B (Novagen). The 
myostatin coding sequence was placed in-frame with 10 histidine residues, 
which have a high affinity for nickel. The resulting construct was transformed 
into DH5 cells and then sequenced to verify the absence of mutations. A 
population of BL21 E. coli competent cells (Invitrogen) were then transformed 
with the recombinant myostatin expression vector, cultured in Luria Bertani 
(LB) broth for 12 h and 0.5 mM isopropyl thio--galactoside (IPTG) added to 
induce production of the myostatin antagonist protein. After collection via 
centrifugation, bacteria were re-suspended in lysis buffer and sonicated. The 
truncated protein was purified from the sonicated cell suspension using Ni-
agarose affinity chromatography (Qiagen). To check the purity of the myostatin 
antagonist, the protein was run on a NuPAGETM 4-12% Bis-Tris gel (Invitrogen) 
and stained with Coomassie Blue stain (Figure 2.1). 
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________________________________________________________________
Figure 2.1: Coomassie blue stain of purified myostatin antagonists 
Three purified myostatin antagonists developed by the FMG group at AgResearch Ltd. Mstn-
ant3 is truncated at the amino acid 300, Mstn-ant4 at amino acid 310 and Mstn-ant5 at amino 
acid 320. As each of the myostatin antagonists were truncated at a different amino acid, the 
overall size (kDa) of each molecule is different, as reflected by their mobility on the gel. 
Furthermore, band intensity increased with increasing concentration (1 µg, 3 µg and 6 µg) of 
myostatin antagonist.  
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2.2.2.2. Burn Injury 
Mice were subjected to the burn injury described for the pilot trial in Section 
2.2.1.1 of this thesis. 
 
2.2.2.3. Administration of Mstn-ant4 or Saline 
Mice were injected subcutaneously with 6 µg/g body weight of saline or Mstn-
ant4 on days 1, 3, 5, 7, 10 and 15 post-injury (Table 3).   
 
2.2.2.4. Sample Collection 
As shown in Table 3, mice were allowed to heal for 2, 4, 7, 14, 21, 28, 35 and 
46 days post-injury. On each of these days, 6 saline-injected mice and 6 Mstn-
ant4-injected mice were sacrificed. The body weight of the animal was recorded 
and both the left (burnt) and right (control) TA muscles were dissected out and 
weighed. For each collection day, the TA muscles from 3 of the saline and 3 of 
the Mstn-ant4-injected mice were processed for histological and ICC analysis, 
by coating the muscle in Tissue Tek O.C.T compound (Sakura) and freezing in 
liquid nitrogen-cooled iso-pentane (BDH) for 10 s. The muscle samples from 
the other 3 mice were frozen directly in liquid nitrogen for RNA extraction. All 
samples were stored at -80ºC until use. 
 
 
Table 3: Injection and Sample Collection Schedule for the In vivo Trial 
Day 0 1 2 3 4 5 7 10 14 15 21 28 35 46 
Injection 
IN
JU
R
Y
 
             
Sample 
Collection              
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2.2.3. Histology 
As described in Section 2.2.2.4, a proportion of the muscle samples obtained 
from the in vivo trial were reserved for histological analysis. In preparation, the 
96 frozen TA muscles were cut on a Leica Cryocut 1800 and the resulting 10 
µm thick sections placed on Esco POLYSINE microscope slides (Biolab 
Scientific). The slides were stored at -20ºC until use.  
 
2.2.3.1. H and E Staining  
The 96 TA muscle sections were defrosted at room temperature (RT) in a humid 
chamber. They were first submerged in Gill’s haematoxylin stain for 4 min, and 
washed with tap water until the water ran clear. The slides were then submerged 
in Scott's tap water for 3 min and rinsed in tap water for 2 min. Slides were then 
stained in eosin for 2 min, washed with tap water until the water ran clear and 
then rinsed for a further 2 min with tap water. The muscle sections were then 
dehydrated by submerging the slides in an ascending ethanol series consisting of 
50% ethanol for 30 s, 70% ethanol for 1 min, 95% ethanol for 1 min, and then 
twice in 100% ethanol for 2 min each. Finally the slides were submerged twice 
in xylene for 5 min each. Cover slips were mounted using xylene-based DPX 
mounting for microscopy (BHD). Muscle sections were viewed using a Leica 
AF6000 microscope (Leica Microsystems Ltd.) with an attached Leica 
DFC300FX digital camera.  Images were captured using the Leica Application 
Suite Version 2.5.0.R1 software (Leica Microsystems Ltd.) and individually 
analysed using Image Pro-Plus 6.0 software. 
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2.2.3.2. Van Gieson Staining 
The 96 TA muscle sections were defrosted at RT in a humid chamber. The 
muscle sections were first fixed in 10% formalin for 5 min at RT, and then 
washed twice with PBS for 4 min each time. Equal volumes of Weigert’s iron 
haematoxylin solution A and solution B were then mixed, and used to stain the 
muscle sections for 10 min. The slides were then washed with tap water until the 
water ran clear, and then rinsed for a further 2 min with tap water. The muscle 
sections were then stained with Van Gieson solution for 10 min and rinsed 
quickly by dipping the slides into tap water three times. The muscle sections 
were then dehydrated by submerging the slides in an ascending ethanol series 
consisting of 50% ethanol with a few drops of picric acid for 30 s, 100% ethanol 
and picric acid for 1 min, 100% ethanol for 2 min and finally twice in xylene for 
5 min each. Cover slips were mounted using xylene-based DPX mounting for 
microscopy (BHD). Muscle sections were viewed using a Leica AF6000 
microscope (Leica Microsystems Ltd.) with an attached Leica DFC300FX 
digital camera.  Images were captured using the Leica Application Suite Version 
2.5.0.R1 software (Leica Microsystems Ltd.) and individually analysed using 
Image Pro-Plus 6.0 software. 
 
2.2.4. Analysis of Gene Expression Using RNA 
As described in Section 2.2.2.4, a proportion of the muscle samples obtained 
from the in vivo trial were reserved for RNA extraction, in order to carry out 
Semi-Quantitative and Real-time PCR reactions to analyse the expression levels 
of various genes.   
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 2.2.4.1. RNA Extraction 
Total RNA was individually extracted from the tissue of 96 TA muscles using 
TRIzol reagent (Invitrogen), following the manufacturer’s protocol.  
 
Each TA muscle was homogenised with 1 ml TRIzol per 50 mg of tissue and 
centrifuged at 12,000 × g for 10 min at 4ºC to pellet cellular debris. 200 µl of 
chloroform per 1 ml TRIzol was added and the samples incubated for 2-3 min 
before centrifugation at 12,000 × g for 15 min at 4ºC. The upper aqueous phase 
was then transferred to a clean Eppendorf tube and an equal volume of 
chloroform added. Tubes were then centrifuged at 12,000 × g for 15 min at 4ºC 
and the upper aqueous layer transferred to a clean tube. 500 µl of isopropanol 
per 1 ml of TRIzol was added to the aqueous phase and the samples were 
incubated at RT for 10 min, and then centrifuged at 12,000 × g for 10 min at 
4ºC. The resulting RNA pellet was washed with 1 ml 75% ethanol made with 
diethyl pyrocarbonate (DEPC)-treated water, then centrifuged at 7,500 × g for 5 
min at 4oC. The RNA pellet was then air-dried for 5-10 min before being re-
suspended in DEPC-treated water. Incubation at 55-60ºC for 10 min completed 
the re-suspension. RNA was stored at -80ºC until use. 
 
2.2.4.2. First Strand cDNA Synthesis 
cDNA for each of the 96 TA muscles was generated using the SuperScript First-
Strand Synthesis System for RT-PCR (Invitrogen), according to the 
manufacturer’s protocol.   
 
1-5 µg of RNA was added to 1 µl of 10 mM dNTPs and 1 µl Oligo(dT)12-18, then 
made up to 10 µl with DEPC-treated water. The sample was incubated at 65ºC 
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for 5 min and then chilled on ice for at least 1 min. To each reaction, 2 µl of 10x 
RT buffer, 4 µl 25 mM MgCl2, 2 µl of 0.1 M DTT, and 1 µl RNase OUT 
Recombinant RNase Inhibitor was added, and then they were incubated at 42ºC 
for 2 min. 1 µl of Superscript II Reverse Transcriptase was added to each 
reaction and then incubated at 42ºC for a further 50 min. The reaction was 
terminated at 70ºC for 15 min and the samples chilled on ice.  1 µl RNaseH was 
added to each tube then incubated for a final 20 min at 37ºC. All cDNA was 
stored at -20ºC. 
 
2.2.4.3. Semi-Quantitative PCR 
PCR amplifications for 4 myogenic genes plus a housekeeping gene were 
carried out for each of the 96 TA muscles using Taq DNA Polymerase (Roche), 
following the manufacturer’s protocol. 
 
Each PCR reaction mix contained 1 µl of template cDNA, 5 µl of 10x PCR 
buffer + Mg++ (Roche), 1 µl of 10 mM dNTPs, 1 µl each of 10 µM forward and 
reverse primer (Table 1) for the specific gene product, 0.5-1 µl of Taq DNA 
Polymerase, and were made up to a total volume of 50 µl with MilliQ sterile 
water. In addition, each reaction mix for the PCR amplifications of 18S and 
mighty also contained 1 µl of 5x Q solution. Thermocycling of the PCR 
reactions was carried out using a BioRad DNAEngine Peltier Thermal Cycler 
(BioRad).  For visualisation, 10 µl of each PCR reaction product was combined 
with 1 µl of 10x DNA loading dye and run on a 1% agarose gel with 5 µl of 
DNA 1kb+ ladder (Invitrogen) as a reference. Gels were exposed to UV light 
using a BioRad Gel Doc 2000. Images were captured and band density 
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measured using BioRad Quantity One 4.4.1 software. Analysis was by relative 
quantitation to the housekeeping gene, 18S.  
 
The PCR amplifications were standardised using cDNA templates derived from 
control mouse TA muscle obtained during the in vivo trial. Various cycle 
numbers were used during standardisation to determine the linear increase in 
product during amplification. The PCR primers are listed in Table 1 and the 
PCR cycle conditions are listed in Table 4.   
 
Table 4: Semi-Quantitative PCR Cycle Conditions 
Product Denaturation Annealing Extension Cycle 
Number 
Mighty 94oC, 20 s 60oC, 45 s 72oC, 1 min 28 
MyoD 94oC, 30 s 60oC, 30 s 72oC, 2 min 26 
Myogenin 94oC, 30 s 62oC, 30 s 72oC, 2 min 32 
Pax7 94oC, 30 s 60oC, 30 s 72oC, 2 min 33 
18S 95oC, 20 s 55oC, 45 s 72oC, 1 min 8 
 
 
2.2.4.4. Real-Time PCR 
Real-Time PCR amplifications were carried out for 6 genes plus a housekeeping 
gene, for each of the 96 TA muscles using LightCycler FastStart DNA 
MasterPLUS SYBR Green 1 (Roche), following the manufacturer’s protocol.  
 
Each Real-Time PCR reaction mix contained 3 µl of template cDNA, 0.5 µl 
each of 10 µM forward and reverse primer (Table 1) for the specific gene 
product, 2 µl LightCycler Master Mix (Roche), and were made up to a total 
volume of 10.5 µl with MilliQ sterile water. In addition, each reaction mix for 
the Real-Time PCR amplifications of Pax7 also contained 1 ul of PCRx. These 
 71 
 
reaction mixes were loaded into precooled LightCycler capillaries and amplified 
using the LightCycler Carousel-Based system (Roche). Absolute quantitation 
and melting curve analyses were carried out using the LightCycler Software 
Version 4.0. These were based on standard curves generated using a series of 
dilutions with known concentrations of cDNA templates derived from control 
mouse TA muscle from the in vivo trial. The Real-Time PCR primers are listed 
in Table 1 and the Real-Time PCR cycle conditions are listed in Table 5.  
 
Table 5: Real-Time PCR Cycle Conditions 
Product Denaturation Annealing Extension Cycle 
Number 
Mighty 95oC, 5 s 60oC, 10 s 72oC, 10 s 45 
MyoD 95oC, 5 s 60oC, 10 s 72oC, 10 s 45 
Myogenin 95oC, 5 s 60oC, 10 s 72oC, 10 s 45 
Pax7 95oC, 5 s 60oC, 10 s 72oC, 10 s 45 
H3.3A 95oC, 5 s 60oC, 10 s 72oC, 10 s 45 
 
 
2.2.5. Analysis of Gene Expression Using Protein 
In order to produce a statistically significant result, all muscle samples obtained 
from the in vivo trial were used for histological analysis and analysis of gene 
expression using RNA. Due to limitations on the number of mice available for 
the in vivo trial and the Animal Ethics Committee not granting approval to 
inflict burn injuries on both hind limbs of each animal, there were no samples 
left to independently extract protein using the normal protocol used in the FMG 
laboratory. However, an alternative protocol was attempted using the  
phenol/ethanol phase normally discarded during the RNA extraction described 
in Section 2.2.4.1 of this thesis.  
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2.2.5.1. Protein Extraction from Phenol/Ethanol Phase  
Protein was extracted from the Phenol/Ethanol phase following the 
manufacturer’s protocol (Invitrogen). 
 
To remove DNA, 0.3 ml of ethanol was added to the phenol/ethanol phase left 
over from the TRIzol RNA extraction, mixed by inversion and incubated at RT 
for 2-3 min. Tubes were then centrifuged at 5000 × g for 5 min at 4ºC. The 
supernatant was transferred to a round-bottom test-tube. To precipitate the 
protein, 3 ml of acetone was added to each tube and incubated at RT for 10 min, 
before centrifuging at 10,000 × g for 10 min at 4ºC. To wash the protein, the 
supernatant was removed and the pellet washed 3 times with 0.3 M guanidine 
hydrochloride (GuHCl) in 95% ethanol. For each wash, 2 ml of the GuHCl 
solution was used and the protein pellet was broken up using a pipette tip. The 
pellet was stored in the GuHCl wash solution for 20 min at RT and then 
centrifuged at 7,500 × g for 5 min at 4ºC to reacquire the pellet. After the final 
wash, the protein pellet was vortexed in 2 ml of 100% ethanol, left in the 
solution for 20 min at RT and then centrifuged at 7,500 × g for 5 min at 4ºC to 
reacquire the pellet. The protein pellet was then redissolved by removing the 
ethanol and air-drying the pellet for 30 min at RT. 500 µl of 1% sodium dodecyl 
sulphate (SDS) was added to each tube, incubated at 50ºC for 10 min then 
centrifuged at 10,000 × g for 10 min at 4ºC. The supernatant was transferred to a 
1.7 ml eppendorf tube and centrifuged at 12,000 × g for 10 min at 4ºC. The 
supernatant was then transferred to a new tube. Protein was stored at -20ºC until 
use.  
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2.2.6. ICC 
As described in Section 2.2.2.4, a proportion of the muscle samples obtained 
from the in vivo trial were reserved for ICC. In preparation, the 96 frozen TA 
muscles were cut on a Leica Cryocut 1800 and the resulting 10 µm thick 
sections placed on Esco POLYSINE microscope slides (Biolab Scientific). The 
slides were stored at -20ºC until use.  
 
2.2.6.1. Mighty ICC  
The 96 tissue sections were thawed in a humid chamber for 5-10 min and then 
an outline circle was drawn around each section with a PAP pen (Zymed 
Laboratories Inc). Sections were blocked with PBS-T + 0.2% bovine serum 
albumin (BSA) + 10% normal donkey serum (NDS) for 2 hours at RT in a 
humid chamber. The primary rabbit anti-Mighty antibody was added at 1:100 in 
PBS-T + 0.2% BSA + 5% NDS and the sections were left overnight at 4ºC in a 
humid chamber. As a negative control, primary antibody was not added to one 
section. The following day, the primary antibody was removed and the slides 
washed three times in PBS for 4 min each wash. Sections were then fixed in 
10% buffered formalin for 5 min at RT in a humid chamber and then washed 
three times in PBS for 4 min each wash. The secondary Amersham biotinylated 
donkey anti-rabbit antibody was added at 1:300 in PBS-T + 0.2% BSA + 5% 
NDS and left for 1 hour at RT in a humid chamber. The secondary antibody was 
then removed and the slide rinsed in PBS, washed three times in PBS-T for 4 
min each time and then rinsed in PBS again. The tertiary Molecular Probes 
Alexa fluor 488 antibody was added at 1:400 in PBS-T + 0.2% BSA and left for 
1 hour at RT in a dark humid chamber. The tertiary antibody was then removed 
and the slides washed two times in PBS for 4 min each wash. To counterstain, 
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DAPI was added to each section at 1:1000 in PBS for 5 min at RT in a dark 
humid chamber and then the slides were washed twice in PBS for 4 min each 
wash. Slides were then dried and coverslips mounted with DakoCytomation 
fluorescent mounting medium (Med-bio Ltd). Slides were stored wrapped in 
tinfoil at 4oC. Muscle sections were viewed using a Leica AF6000 microscope 
(Leica Microsystems Ltd.) with an attached Leica DFC300FX digital camera.  
Images were captured using the Leica Application Suite Version 2.5.0.R1 
software (Leica Microsystems Ltd.) and individually analysed using simple 
visual estimation. 
 
2.2.6.2. Mac1 ICC 
The 96 tissue sections were thawed in a humid chamber for 5-10 min and then 
an outline circle was drawn around each section with a PAP pen (Zymed 
Laboratories Inc). Sections were blocked with PBS-T + 0.2% BSA + 10% NDS 
for 30 min at RT in a humid chamber. The primary goat anti-Mac1 antibody was 
added at 1:100 in PBS-T + 0.2% BSA + 5% NDS and the sections were left 
overnight at 4ºC in a humid chamber. As a negative control, primary antibody 
was not added to one section. The following day, the primary antibody was 
removed and the slides washed three times in PBS for 4 min each wash. 
Sections were then fixed in 10% buffered formalin for 5 min at RT in a humid 
chamber and then washed three times in PBS for 4 min each wash. The 
secondary Amersham biotinylated donkey anti-sheep/goat antibody was added 
at 1:300 in PBS-T + 0.2% BSA + 5% NDS and left for 1 hour at RT in a humid 
chamber. The secondary antibody was then removed and the slide rinsed in 
PBS, washed three times in PBS-T 0.2% for 4 min each time and then rinsed in 
PBS again. The tertiary Molecular Probes Alexa fluor 488 antibody was added 
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at 1:400 in PBS-T + 0.2% BSA and left for 1 hour at RT in a dark humid 
chamber. The tertiary antibody was then removed and the slides washed two 
times in PBS for 4 min each wash. To counterstain, DAPI was added to each 
section at 1:1000 in PBS for 5 min at room temperature in a dark humid 
chamber and then the slides were washed twice in PBS for 4 min each wash. 
Slides were then dried and coverslips mounted with DakoCytomation 
fluorescent mounting medium (Med-bio Ltd). Slides were stored wrapped in 
tinfoil at 4oC. Muscle sections were viewed using a Leica AF6000 microscope 
(Leica Microsystems Ltd.) with an attached Leica DFC300FX digital camera.  
Images were captured using the Leica Application Suite Version 2.5.0.R1 
software (Leica Microsystems Ltd.) and macrophages individually counted 
using Image Pro-Plus 6.0 software. 
 
2.2.7. Statistical Analysis 
Due to the skewed nature of the raw data, natural log (ln)
 
transformations were 
applied to all data prior to statistical analysis. Analysis of variance (ANOVA) 
was then carried out on the transformed data, with each response variable, 
treatment (saline versus Mstn-ant4), muscle condition (burn versus control), 
time (days after injury) and their interactions followed at each individual time 
point by Student t-tests, using the pooled standard error from the ANOVA.    
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Chapter Three: Results 
 
 
3.1. Development of the Muscle Burn Injury Model 
For the purpose of developing a murine muscle burn injury model for this thesis, 
several previously published burn injury methods (see Section 1.7.1) were 
discussed with the Ruakura Animal Ethics Committee. The use of lasers would 
have been the preferred method to produce consistent burn injuries; however 
this type of equipment was not available at the time of the in vivo trial. 
Therefore, a cold burn injury was developed and tested, which involved a pellet 
of dry ice being applied to the exposed TA muscle of a mouse for 30 s. 
However, this did not generate a sufficient burn injury to the muscle. A branding 
method using a metal bar (1.5 mm wide and 7 mm long) was then adopted, 
where the bar was cooled in liquid nitrogen and then applied to the exposed TA 
muscle of the mouse for 30 s. Again, this did not produce the expected damage 
to the muscle because the metal bar was too small to retain the cold temperature, 
but the size of the bar was limited by the small size of the mouse TA muscle. 
The use of drops of liquid nitrogen directly onto the TA muscle was then 
discussed, but it was predicted this would produce a burn injury of inconsist 
size. Therefore a hot burn injury model was eventually designed and tested. 
Specifically, the metal bar was heated in a Bunsen burner flame until it was red-
hot and then applied to the exposed TA muscle of the mouse for 5 s. A severe 
burn injury was produced, as shown in Figures 3.1 and 3.2. Approval for this 
method was granted by both the Ruakura Animal Ethics Committee and the 
University of Waikato Ethics Committee.  
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Figure 3.1: The murine muscle burn injury model  
 
A) A red-hot metal rod 1.5 mm wide and 7 mm long was applied directly to the TA muscle of 
anaesthetised mice for 5 s. B) This produced a severe burn injury to the muscle. 
 
 78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
________________________________________________________________ 
Figure 3.2: Burn injury damage to mouse tibialis anterior muscle 
 
A) Haematoxylin and eosin staining of uninjured muscle. Muscle fibres are stained pink and 
nuclei are stained purple. B) Applying a red-hot metal rod to the TA for 5 seconds produced a 
severe burn injury. Images were taken on day 2 post-injury. Magnification: 200x. 
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As discussed in Section 2.1.1 of this thesis, mice that were approximately 9 
months of age were used for the in vivo trial. Studies have shown that the 
regenerative capacity of skeletal muscle decreases with age, and this is related to 
a decrease in satellite cell number and activity (Shefer et al., 2006; Le Grand & 
Rudnicki, 2007). Therefore, younger mice would recover quite quickly from the 
burn injury and any improvements in wound healing as a result of Mstn-ant4 
administration would be difficult to detect. In contrast, at 9 months of age, 
skeletal muscle regeneration occurs more slowly in mice, allowing the effect of 
Mstn-ant4 administration on wound healing and muscle regeneration to be more 
accurately evaluated.  
 
3.2. Pilot Trial  
A pilot trial was carried out with the assistance of Mônica Senna Salerno of the 
FMG group, to determine a suitable duration for the main in vivo trial and the 
frequency of sample collection. A previous notexin injury trial undertaken by 
the FMG group at AgResearch (Siriett et al., 2007) spanned a time period of 0 to 
28 days and so this same duration was used for the pilot trial. However, results 
suggested that due to the severity of the burn injury, the main in vivo trial should 
be extended to 46 days to allow adequate healing. In addition, the frequency of 
sample collection needed to be slightly modified, with the earliest time-points 
changed to days 2 and 4 post-injury instead of day 5, to ensure no early 
regeneration events were missed.  
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3.3. In vivo Trial  
3.3.1. Effect of Muscle Burn Injury on Body and Muscle Weight 
The body weight of each of the 96 mice involved in the in vivo trial was 
recorded on the day of injury (day 0) and then again on the day of euthanasia. 
As shown in Figure 3.3, a decrease in body weight was observed in both the 
saline-treated and Mstn-ant4-treated mice in the first 2 weeks following the burn 
injury. The Mstn-ant4-treated mice recovered from this weight loss earlier than 
the saline-treated mice, with body weight exceeding original levels by day 21 
post-injury, while the saline-injected mice still showed a decreased body weight. 
However, both the saline-treated and Mstn-ant4-treated mice displayed erratic 
patterns of weight gain or weight loss at the subsequent time points. Overall, 
there was no significant difference in body weight change between the saline-
treated and the Mstn-ant4-treated mice during the course of the in vivo trial.   
 
The weight of both the left (burnt) and right (control) TA muscle for each of the 
96 mice involved in the trial were also measured at the time of excision. 
ANOVA analysis revealed no significant differences between the weight of the 
saline-treated and Mstn-ant4-treated burnt TA muscles. Similarly, no significant 
treatment differences were found when the control muscles were compared 
(Figure 3.4). Within each treatment group the burnt TA muscles appeared to 
decrease in weight over time in relation to the control TA muscles. Figure 3.5 
shows the saline-treated burnt TA muscles weighed significantly less (p<0.01) 
than the control TA muscles at days 28 and 46. While the Mstn-ant4-treated 
burnt TA muscles were significantly lower in weight than the control muscles at 
days 21 and 28 (p<0.05) and days 35 and 46 (p<0.01) post-injury. However,  
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Figure 3.3: Change in body weight during muscle regeneration following burn injury 
 
Over the first 14 days following burn injury, a decrease in body weight was observed in both the 
saline-treated (light bars) and Mstn-ant4-treated (dark bars) mice. The Mstn-ant4-treated mice 
recovered from this weight loss earlier than the saline-treated mice (day 21), but the erratic 
pattern of weight loss and weight gain at the subsequent time points leads to no significant 
treatment differences in body weight change overall. Values represent the mean of 6 animals ± 
SED. SED calculated as the pooled standard error of all animals. Weight change is relative to the 
animal’s weight at Day 0. **p<0.01 by Student’s t-test.  
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Figure 3.4: Comparison of right and left tibialis anterior weights between the two treatment 
groups 
 
A) There were no significant differences in the weights of the right (control) TA muscles 
between the saline-treated and Mstn-ant4-treated mice over the trial period. B) There were no 
significant differences in the weights of the left (burnt) TA muscle between the saline-treated 
and Mstn-ant4-treated mice over the trial period. Values represent the mean of 3 animals ± SED. 
SED calculated as the pooled standard error of all animals.  
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Figure 3.5: Change in weight of tibialis anterior during muscle regeneration following burn 
injury 
 
A) The weight of the saline-treated burnt TA muscles were significantly lower than the control 
TA muscles at day 28 and 46 post-injury. B) The weight of the Mstn-ant4-treated burnt TA 
muscles were significantly lower than the control TA muscles at day 21, 28, 35 and 46 post-
injury. However, no overall significant treatment differences were detected by ANOVA 
analysis. Values represent the mean of 3 animals ± SED. SED calculated as the pooled standard 
error of all animals. *p<0.05 and **p<0.01 by Student’s t-test. 
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ANOVA analysis detected no overall differences between the weights of burnt 
and control muscles over time, for both the saline-treated and Mstn-ant4-treated 
animals. 
 
3.3.2. Effect of Burn Injury on the Histological Profile of Muscle 
3.3.2.1. CFN 
The presence of CFN in skeletal muscle fibres is one of the key features which 
characterise skeletal muscle regeneration (see Section 1.7.2). Figure 3.6 shows 
the expected steady increase in the number of CFN present in the muscle fibres 
of both the Mstn-ant4 and saline-treated mice following the burn injury. From 
day 21 onwards, the number of CFN present in the burnt muscle for each 
treatment group was significantly higher (p<0.001) than that of their respective 
control muscles. When the burnt and control muscles are analysed 
independently (Figure 3.7) there is some variation between the Mstn-ant4 and 
saline-treated control muscles. There were significantly fewer numbers of CFN 
at days 21 (p<0.05), 28 (p<0.001) and 35 (p<0.05) post-injury in Mstn-ant4-
treated mice compared to the saline-treated mice. This lead to a slight treatment 
effect being detected by ANOVA analysis, which suggested higher levels of 
CFN were generated from the saline-treatment overall. However, when the 
number of CFN in the burnt muscles was analysed, no overall treatment 
differences were detected despite the saline treated mice initially showing a 
higher level of CFN than the Mstn-ant4 treated mice. Interestingly, by day 46 
post-injury it appeared that the burnt muscle from Mstn-ant4-treated mice had 
slightly more CFN than the saline-treated, but this difference is not statistically 
significant. The number of muscle fibres containing CFN showed very similar 
trends to those described for the absolute number of CFN (data not shown). 
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Figure 3.6: Centrally formed nuclei in the control and burnt muscles of Mstn-ant4 and 
saline-treated mice.  
 
A) The number of CFN in the muscle fibres of both Mstn-ant4 and saline-treated mice increased 
following the burn injury. From day 21 onwards, the number of CFN in the burnt muscles was 
significantly higher (p<0.001) than the respective control muscles. Values represent the mean of 
3 animals ± SED. SED calculated as the pooled standard error of all animals.**p<0.01 by 
Student’s t-test. B) White arrows highlight some CFN in the burnt muscle of Mstn-ant4-treated 
mice at day 28 post-injury, which are not present in the corresponding control muscle. 
Magnification: 200x. 
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Figure 3.7: Centrally formed nuclei in the control and burnt muscles of Mstn-ant4 and 
saline treated mice. 
 
A) Variability exists between the number of CFN in the treatment controls. The number of CFN 
in Mstn-ant4-treated mice were significantly lower than the saline-treated mice at day 21 
(p<0.05), 28 (p<0.001) and 35 (p<0.05) post-injury. B) In the burnt muscles, saline-treated mice 
appeared to initially have more CFN than the Mstn-ant4-treated mice. However, no overall 
significant treatment differences were detected by ANOVA analysis. Values represent the mean 
of 3 animals ± SED. SED calculated as the pooled standard error of all animals. *p<0.05 and 
**p<0.01 by Student’s t-test.  
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In addition to analysing the absolute values of CFN and the number of fibres 
containing CFN, the ratio of CFN to CFN fibre number was also examined for  
both treatment groups. No significant differences between the CFN to CFN fibre 
ratio in Mstn-ant4 and saline-treated mice were found in the control muscles 
(Figure 3.8). However, Figure 3.8 shows that the CFN to CFN fibre ratio was 
signficantly lower (p<0.05) in the burnt muscle of Mstn-ant4-treated mice at day 
4 post-injury compared to the saline-treated mice. At day 14 post-injury this was 
reversed, with the Mstn-ant4-treated mice having a significantly higher (p<0.01) 
ratio of CFN to CFN fibre number than the saline-treated mice. However, no 
overall treatment differences were detected by ANOVA analysis. 
 
The ratios of CFN and CFN fibre number to the damaged area of the burnt 
muscle sections were also evaluated. In both instances, the Mstn-ant4-treated 
and saline-treated mice showed very similar trends with no significant treatment 
differences detected, except for a slightly higher (p<0.05) CFN fibre number to 
damaged area ratio at day 46 post-injury in the Mstn-ant4-treated mice (data not 
shown). 
  
3.3.2.2. Fibrogenesis 
As discussed in Section 1.7.2 of this thesis, Van Gieson staining can be used as 
an indicator for the level of fibrogenesis occurring in a tissue, by specifically 
detecting levels of collagen deposition. As collagen deposition is not one of the 
initial stages of the inflammatory response, a gradual increase would be 
expected over time. Figure 3.9 shows this steady increase in the levels of 
collagen present in the tissues of both the Mstn-ant4 and saline-treated mice 
following the burn injury.  From day 21 onwards, the amount of collagen  
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Figure 3.8: The ratio of CFN to CFN fibre number in the control and burnt muscles of 
Mstn-ant4 and saline-treated mice. 
 
A) There were no significant treatment differences between the CFN/CFN fibre ratio in the 
control muscles of Mstn-ant4 and saline-treated mice. B) At day 4 post-injury, the CFN/CFN 
fibre ratio was significantly higher (p<0.05) in the burnt muscles of saline-treated mice, 
compared to the Mstn-ant4-treated mice. This was reversed at day 14 post-injury (p<0.01). 
However, no overall significant treatment differences were detected by ANOVA analysis. 
Values represent the mean of 3 animals ± SED. SED calculated as the pooled standard error of 
all animals. *p<0.05 and **p<0.01 by Student’s t-test. 
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Figure 3.9: Collagen deposition in the control and burnt muscles of Mstn-ant4 and saline-
treated mice.  
 
A) Collagen deposition in the burnt muscles of both Mstn-ant4 and saline-treated mice increased 
over time. From day 21 onwards, the levels of collagen in the burnt muscles of saline-treated 
mice were significantly higher (p<0.01) than the saline control muscles. The same trend was 
seen between the Mstn-ant4-treated burnt and control muscles from day 28 onwards. Values 
represent the mean of 3 animals ± SED. SED calculated as the pooled standard error of all 
animals. **p<0.01 by Student’s t-test. B) Collagen (red) can be detected in the burnt muscles by 
Van Geison staining. Magnification: 200x. 
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deposition in the burnt muscle of saline-treated mice was significantly higher 
(p<0.01) than the saline control muscle. The same trend was observed between 
the Mstn-ant4-treated muscles from day 28 onwards, indicating that 
administration of Mstn-ant4 may cause a slight delay in collagen deposition 
following a burn injury. When the burnt and control muscles are analysed 
independently (Figure 3.10), no significant differences in the amount of collagen 
in the control muscles of saline and Mstn-ant4-treated mice were detected. In the 
burnt muscles however, the saline treated mice had a signficantly higher 
(p<0.01) level of collagen deposition at day 2 post-injury, compared to the 
Mstn-ant4-treated mice, but this was reversed at day 35 when the Mstn-ant4-
treated mice showed a significantly higher level (p<0.01) of collagen deposition 
in the muscle. However, ANOVA analysis did not detect any overall significant 
differences between the two treatment groups.  
 
To supplement the results generated from the Van Gieson staining, gene 
expression levels of the two most abundant types of collagen, types I and III, 
were evaluated in the burnt and control muscles of Mstn-ant4 and saline-treated 
mice using Real-Time PCR, and normalised to the housekeeping gene H3.3A 
(Figures 3.11 and 3.12). ANOVA analysis detected a significant effect for 
muscle condition, with an overall tendancy for collagen I and III expression to 
be significantly higher (p<0.01) in the burnt muscles of both Mstn-ant4 and 
saline-treated mice compared to their relative control muscles (data not shown). 
When the burnt and control muscles are analysed independently, only one 
significant difference occurring at day 4 post-injury is detected. Specifically, 
collagen I (p<0.05) and III (p<0.01) expression was significantly higher in the  
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Figure 3.10: Collagen deposition in the control and burnt muscles of Mstn-ant4 and saline-
treated mice.  
 
A) There were no significant treatment differences in the level of collagen deposition between 
the control muscles of Mstn-ant4 and saline-treated mice. B) In the burnt muscles, the amount of 
collagen deposition in the saline-treated mice was significantly higher (p<0.01) than the Mstn-
ant4 mice at day 2 post-injury. This was reversed at day 35 post-injury (p<0.01). However, no 
overall significant treatment differences were detected by ANOVA analysis. Values represent 
the mean of 3 animals ± SED. SED calculated as the pooled standard error of all animals.  
* p<0.05 and **p<0.01 by Student’s t-test. 
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3.11: Collagen I gene expression in the control and burnt muscles of Mstn-ant4 and saline-
treated mice 
 
A)  Collagen I gene expression was significantly higher (p<0.05) in the control muscles of 
saline-treated mice at day 4 post-injury compared to the Mstn-ant4-treated mice. B) There were 
no significant differences in collagen I expression between the burnt muscles of Mstn-ant4 and 
saline-treated mice. Values represent the mean of 3 animals ± SED. SED calculated as the 
pooled standard error of all animals. *p<0.05 by Student’s t-test. RFU=Relative Fluorescent 
Units.  
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3.12: Collagen III gene expression in the control and burnt muscles of Mstn-ant4 and 
saline-treated mice 
 
A)  Collagen III gene expression was significantly higher (p<0.01) in the control muscles of 
saline-treated mice at day 4 post-injury compared to the Mstn-ant4-treated mice. B) There were 
no significant differences in collagen III expression between the burnt muscles of Mstn-ant4 and 
saline-treated mice. Values represent the mean of 3 animals ± SED. SED calculated as the 
pooled standard error of all animals. **p<0.01 by Student’s t-test. RFU=Relative Fluorescent 
Units.  
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saline-treated mice compared to the Mstn-ant4-treated mice. Overall, no 
significant treatment differences in collagen I and III expression were detected 
by ANOVA analysis, therefore supporting the results generated by Van Gieson 
staining of the muscle sections.  In addition, the fibrotic index, which is the ratio 
of collagen type III to collagen type I gene expression (see Section 1.7.2) was 
also calculated for these muscle samples, but no significant differences between 
the treatment groups were detected (data not shown).   
 
3.3.3.  Inflammatory Cell Response to Burn Injury 
A key event of the inflammatory response is the infiltration of macrophages to 
the wound site, which can be detected using a Mac1 ICC (see Section 1.7.2). As 
expected, no macrophages were detected in the control muscles of saline and 
Mstn-ant4-treated mice, as macrophages are specifically associated with the 
inflammatory response and wound healing. Therefore, the number of 
macrophages present in the burnt muscles was significantly higher (p<0.001) 
than their respective control muscles (data not shown). Moreover, Figure 3.13 
shows an overall decline in macrophage infiltration over time, which ANOVA 
analysis detected as highly significant (p<0.001). However, further analyses of 
the burnt muscles revealed no significant differences in the level of macrophage 
infiltration between the Mstn-ant4 and saline-treated burnt muscles.  
 
3.3.4. Expression of Myogenic Genes in Control and Burnt Muscles 
As mentioned in Section 3.3.2.2 of this thesis, a useful tool for evaluating 
expression patterns of genes is to amplify target sequences using PCR. Two 
different types of PCR reactions were used in this thesis, first Semi-Quantitative 
PCR and then Real-Time PCR.  
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Figure 3.13: Macrophage infiltration in the control and burnt muscles of Mstn-ant4 and 
saline-treated mice.  
 
A) There were no significant differences between the levels of infiltrating macrophages in the 
burnt muscles of Mstn-ant4 and saline-treated mice. Overall, levels of infiltrating macrohpages 
decreased over time, as expected. Values represent the mean of 3 animals ± SED. SED 
calculated as the pooled standard error of all animals. B) Macrophage infiltration was evaluated 
using a Mac1 ICC. Macrophages appear as green dots in the burnt muscles, but were not present 
in the control muscles. Magnification: 200x. 
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As previously shown in Section 3.3.2.2, it is common practise to normalise gene 
expression to a housekeeping gene when carrying out PCR amplifications, in 
order to control for variations in sample concentrations and loading. For this 
thesis, the four myogenic genes of interest were normalised to 18S rRNA for the 
Semi-Quantitative PCRs and H3.3A for the Real-Time PCRs. Both of these 
housekeeping genes are widely used in many biological science laboratories, 
including FMG at AgResearch Ltd. Unfortunately no data was obtained for the 
day 21 and day 28 burnt muscles of the saline-treated mice, as a result of human 
error during the RNA extraction. 
 
3.3.4.1. Mighty 
Mighty is a downstream target of myostatin (see Section 1.7.2). Figure 3.14, 
shows the level of mighty expression detected by Semi-Quantitative PCR in the 
control muscles of Mstn-ant4 and saline-treated mice was very similar 
throughout the in vivo trial, except at day 14 post-injury when mighty was 
significantly (p<0.01) upregulated in the Mstn-ant4-treated mice. In contrast, the 
saline-treated mice had significantly higher (p<0.05) levels of mighty expression 
at day 14 post-injury compared to the Mstn-ant4-treated mice. ANOVA analysis 
detected a significant interaction (p<0.01) between treatment and muscle 
condition, with an overall tendency for mighty expression to be higher in the 
burnt muscles of saline-treated mice compared to the Mstn-ant4-treated mice, 
for the majority of the trial duration. By day 46 however, the level of mighty 
expression was higher in the Mstn-ant4-treated mice compared to the saline-
treated mice, although this difference was not statistically significant by 
Student’s t-test. Interestingly, both the control and burnt muscles of Mstn-ant4 
and saline-treated mice showed a large increase in mighty expression between  
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_______________________________________________________________ 
Figure 3.14: Mighty gene expression in the control and burnt muscles of Mstn-ant4 and 
saline-treated mice (Semi-Quantitative PCR).  
 
A) Mighty expression in the control muscle of Mstn-ant4 and saline-treated mice was similar 
throughout the in vivo trial, except at day 14 post-injury when mighty was significantly (p<0.01) 
upregulated in the Mstn-ant4-treated mice.  B) Saline-treated mice had significantly higher 
levels of mighty expression in the burnt muscles at day 14 (p<0.05) post-injury. An overall 
tendancy for mighy expression to be higher in the saline-treated mice was detected by ANOVA 
analysis (p<0.01). Values represent the mean of 3 animals ± SED. SED calculated as the pooled 
standard error of all animals. *p<0.05 and **p<0.01 by Student’s t-test. Bands are indicative of 
overall results. N/A = samples lost due to human error.  
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days 2 and 4 post-injury, which is consistent with other injury models (Senna 
Salerno et al., submitted).  
 
Conflicting results were generated from the Real-Time PCRs. Figure 3.15 shows 
more variation in the levels of mighty gene expression in the control muscles of 
Mstn-ant4 and saline-treated mice. Specifically, mighty expression was 
significantly higher in the Mstn-ant4-treated mice at days 2 (p<0.05), 4 and 28 
(p<0.01), compared to the saline-treated mice. Mighty expression was also 
significantly higher in the burnt muscles of Mstn-ant4-treated mice at days 2 
(p<0.05) and 4 (p<0.01) post-injury, compared to the saline-treated mice. A 
significant (p<0.01) treatment effect was detected by ANOVA analysis, with an 
overall tendency for mighty expression to be higher in the Mstn-ant4-treated 
mice than saline-treated mice. In agreement with the Semi-Quantitative PCR 
results, Real-Time PCR also indicated a large increase in mighty expression 
between days 2 and 4 for both the control muscles of Mstn-ant4 and saline-
treated mice and also for the burnt muscles of Mstn-ant4 treated mice. However, 
the burnt muscles of saline-treated mice no longer showed this trend.    
 
In addition to PCRs, ICC can also be a useful tool for evaluating gene 
expression. Mighty ICCs were carried out on the burnt and control muscle 
samples of Mstn-ant4 and saline-treated mice. Based on visual estimation, no 
significant differences were apparent between the two treatment groups. 
However, the extent of mighty expression in the burnt muscles did increase over 
the duration of the in vivo trial, as expected (Figure 3.16). 
 
 99 
 
 
________________________________________________________________ 
Figure 3.15: Mighty gene expression in the control and burnt muscles of Mstn-ant4 and 
saline-treated mice (Real-Time PCR).  
 
A) Mighty gene expression was significantly higher (p<0.01) in the control muscles of Mstn-
ant4 mice at day 4 and 28 post-injury compared to saline-treated mice. B) Mstn-ant4-treated 
mice had significantly higher levels of mighty gene expression at day 2 (p<0.05) and 4 (p<0.01) 
post-injury compared to saline-treated mice.  An overall tendancy for mighty expression to be 
higher in the Mstn-ant4-treated mice was detected by ANOVA analysis (p<0.01). Values 
represent the mean of 3 animals ± SED. SED calculated as the pooled standard error of all 
animals. *p<0.05 and **p<0.01 by Student’s t-test. RFU=Relative Fluorescent Units.  
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________________________________________________________________ 
Figure 3.16: Mighty gene expression in the control and burnt muscles of Mstn-ant4 and 
saline-treated mice (ICC).  
 
Mighty gene expression was detected using ICC. Mighty expression is stained green and nuclei 
are blue. No significant treatment differences in mighty expression were evident by visual 
estimation; however expression in burnt muscles did increase over time compared to control 
muscles. Magnification: 200x. 
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3.3.4.2. MyoD and Myogenin 
As discussed in Section 1.7.2, MyoD and myogenin are MRFs that are essential 
for the growth of muscle during skeletal muscle development. The levels of 
MyoD expression detected by Semi-Quantitative PCR in the burnt and control 
muscles of Mstn-ant4 and saline-treated mice, are shown in Figure 3.17. There 
was some variation in MyoD expression in the control muscles, with 
significantly higher (p<0.05) levels in the Mstn-ant4-treated mice at day 14 
post-injury compared to the saline-treated mice. In the burnt muscles, MyoD 
expression was significantly higher (p<0.05) in the saline treated mice at day 14 
post-injury compared to the Mstn-ant4-treated mice. ANOVA analysis detected 
a significant interaction (p<0.01) between treatment and muscle condition, with 
an overall tendency for MyoD expression to be higher in the burnt muscles of 
saline-treated mice compared to Mstn-ant4-treated mice.  
 
In contrast, the Real-Time PCR results in Figure 3.18 show MyoD expression to 
be higher (p<0.01) in the saline-treated mice at day 4 post-injury compared to 
the Mstn-ant4-treated mice. An erratic pattern of MyoD expression emerges in 
the burnt muscles. The Mstn-ant4-treated mice had significantly higher (p<0.05) 
levels of MyoD expression at days 2 and 35 post- injury, compared to the saline-
treated mice. However, the saline-treated mice had significantly higher (p<0.05) 
levels of MyoD expression at days 14 and 46 post-injury, compared to the Mstn-
ant4-treated mice. Interestingly, the standard curve used to generate these MyoD 
gene expression measurements had the largest error associated with it, compared 
to the standard curves for the other genes. Due to time constraints, this 
variability in the MyoD standard curve could not be improved upon and  
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________________________________________________________________ 
Figure 3.17: MyoD gene expression in the control and burnt muscles of Mstn-ant4 and 
saline-treated mice (Semi-Quantitative PCR). 
 
A) At day 14 post-injury, MyoD expression was significantly higher (p<0.05) in the control 
muscles of Mstn-ant4-treated mice. B) An overall tendancy for MyoD expression to be higher in 
the burnt muscle of saline-treated mice was detected by ANOVA analysis, with a significant 
difference occurring at day 14 (p<0.05) post-injury. Values represent the mean of 3 animals ± 
SED. SED calculated as the pooled standard error of all animals. *p<0.05 by Student’s t-test. 
Bands are indicative of overall results. N/A = samples lost due to human error.  
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________________________________________________________________ 
Figure 3.18: MyoD gene expression in the control and burnt muscles of Mstn-ant4 and 
saline-treated mice (Real-Time PCR). 
 
A) At day 4 and 28 post-injury, MyoD expression was significantly higher (p<0.01) in the 
control muscles of saline-treated mice compared to Mstn-ant4-treated mice. B) MyoD 
expression was significantly higher in the burnt muscles of saline-treated mice at day 14 and 46 
post-injury (p<0.05) but was significantly higher in the Mstn-ant4-treated mice at day 2 and 35 
(p<0.05). No significant treatment differences were detected by ANOVA analysis. Values 
represent the mean of 3 animals ± SED. SED calculated as the pooled standard error of all 
animals. *p<0.05 and **p<0.01 by Student’s t-test. RFU=Relative Fluorescent Units.  
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therefore may account for the erratic pattern of gene expression observed. No 
overall significant treatment differences in MyoD gene expression between the 
Mstn-ant4 and saline-treated mice were detected by ANOVA analysis. 
 
Figure 3.19 illustrates the expression levels of myogenin detected by Semi-
Quantitative PCR in the burnt and control muscles of Mstn-ant4 and saline-
treated mice. Again, some variation in the control muscles was present. 
Myogenin expression was significantly higher (p<0.05) in the control muscles 
of Mstn-ant4-treated mice at days 4 and 28 post-injury, but this was reversed at 
day 21 post-injury with the saline-treated mice expressing significantly higher 
(p<0.05) levels of myogenin than Mstn-ant4-treated mice. No significant 
differences in the levels of myogenin expression between the Mstn-ant4 and 
saline treated mice were detected in the burnt muscles. Therefore, no overall 
treatment differences were detected by ANOVA analysis.  Similarly, Figure 
3.20 shows that no significant differences in myogenin expression in either the 
control or burnt muscles of Mstn-ant4 and saline-treated mice were detected by 
Real-Time PCR. Unlike the Semi-Quantitative PCR results however, the Real-
Time results show a large increase in myogenin expression between days 2 and 
4 post-injury in the burnt muscles of Mstn-ant4 and saline-treated mice before a 
gradual decrease over time to return to expression levels similar to those 
observed at day 2. This is similar to the trends observed for mighty gene 
expression.  
 
3.3.4.3. Pax7 
Pax7 has been identified as a key factor involved in satellite cell activity and 
self-renewal (see Section 1.7.2). The levels of Pax7 expression detected by  
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________________________________________________________________ 
Figure 3.19: Myogenin gene expression in the control and burnt muscles of Mstn-ant4 and 
saline-treated mice (Semi-Quantitative PCR).  
 
A) At day 4 and 28 post-injury, myogenin expression was significantly higher (p<0.05) in the 
control muscles of Mstn-ant4-treated mice. However, saline-treated mice showed significantly 
higher (p<0.05) levels of myogenin expression at day 21 post-injury. B) There were no 
significant differences between the levels of myogenin expression in the burnt muscles of Mstn-
ant4 and saline- treated mice. Values represent the mean of 3 animals ± SED. SED calculated as 
the pooled standard error of all animals. *p<0.05 by Student’s t-test. Bands are indicative of 
overall results. N/A = samples lost due to human error.  
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Figure 3.20: Myogenin gene expression in the control and burnt muscles of Mstn-ant4 and 
saline-treated mice (Real-Time PCR).  
 
A) There were no significant differences in myogenin expression between the control muscles of 
Mstn-ant4 and saline-treated mice. B) There were no significant differences in myogenin 
expression between the burnt muscles of Mstn-ant4 and saline-treated mice. Values represent the 
mean of 3 animals ± SED. SED calculated as the pooled standard error of all animals. 
RFU=Relative Fluorescent Units. RFU=Relative Fluorescent Units.  
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Semi-Quantitative PCR in the burnt and control muscles of Mstn-ant4 and 
saline-treated mice are shown in Figure 3.21. No significant differences in Pax7 
expression in either the control or burnt muscles of Mstn-ant4 and saline-treated 
mice were detected. However, a significant (p<0.01) treatment effect was 
detected by ANOVA analysis, with an overall tendency for Pax7 expression to 
be higher in the saline-treated mice than the Mstn-ant4-treated mice. 
Interestingly, like mighty expression, both the control and burnt muscles of 
Mstn-ant4 and saline-treated mice showed a large increase in Pax7 expression 
between days 2 and 4 post-injury. 
 
No significant differences in Pax7 expression between the Mstn-ant4 and saline-
treated mice were detected by Real-Time PCR (Figure 3.22). Although not 
detected by ANOVA analysis, it appears the overall trend for Pax7 expression to 
be higher in the saline-treated mice, as detected by Semi-Quantitative PCR, was 
reversed in the results generated by Real-Time PCR. Furthermore, the trend for 
Pax7 expression to increase between days 2 and 4 post-injury was no longer 
evident in the control muscles, and a decrease in Pax7 expression between days 
2 and 4 was observed in the burnt muscles of Mstn-ant4 and saline-treated mice 
analysed by Real-Time PCR.  
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Figure 3.21: Pax7 gene expression in the control and burnt muscles of Mstn-ant4 and 
saline-treated mice (Semi-Quantitative).  
 
A) No significant differences in Pax7 expression were detected in the control muscles of Mstn-
ant4 and saline-treated mice. B) No significant differences in Pax7 expression were detected in 
the burnt muscles of Mstn-ant4 and saline-treated mice. However, an overall tendancy for Pax7 
expression to be higher (p<0.01) in the burnt muscle of saline-treated mice was detected by 
ANOVA analysis. Values represent the mean of 3 animals ± SED. SED calculated as the pooled 
standard error of all animals. Bands are indicative of overall results. N/A = samples lost due to 
human error.  
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Figure 3.22: Pax7 gene expression in the control and burnt muscles of Mstn-ant4 and 
saline-treated mice (Real-Time PCR).  
 
A) There were no significant differences in Pax7 expression between the control muscles of 
Mstn-ant4 and saline-treated mice. B) There were no significant differences in Pax7 expression 
between the burnt muscles of Mstn-ant4 and saline-treated mice. No overall significant 
treatment differences were detected by ANOVA analysis. Values represent the mean of 3 
animals ± SED. SED calculated as the pooled standard error of all animals. RFU=Relative 
Fluorescent Units.  
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Chapter Four: Discussion and Future Direction 
 
 
4.1. Discussion 
4.1.1. Introduction 
Myostatin is a growth and differentiation factor that belongs to the TGF- 
superfamily of genes (McPherron et al., 1997; Thomas et al., 2000). Mutations 
or deletions in the myostatin gene lead to the heavy muscling phenotypes seen in 
various breeds of cattle, sheep and dogs, and also in myostatin knock-out mice 
(Kambadur et al., 1997; McPerron & Lee, 1997; Berry et al., 2002; Schuelke et 
al., 2004). More recently, a human child with the heavy muscling phenotype 
was also found to carry a mutation in the myostatin gene (Walsh & Celeste, 
2005). Conversely, increased expression of myostatin has been linked to various 
muscle wasting conditions induced by ageing or disease. Myostatin is therefore 
regarded as a strong inhibitor of muscle growth. In addition, myostatin has also 
been shown to control satellite cell activation post-natally, and is considered a 
potent negative regulator of muscle regeneration and repair as well (McCroskery 
et al., 2003; Bishop et al., 2005). The ability to block myostatin function would 
therefore have enormous potential in the treatment of muscle injuries and 
various muscle wasting conditions.  
 
The FMG group at AgResearch Ltd. have begun to investigate this concept. By 
truncating the biologically active mature myostatin sequence at different amino 
acids, they have produced several myostatin antagonists that have shown 
promising results in the in vitro studies carried out so far. Specifically, all the 
antagonists elicited a strong antagonistic effect on both endogenous and 
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exogenous myostatin. Furthermore, the ability of myostatin to influence the 
chemotactic capacity of myogenic cells was interupted by all antagonists when 
tested in vitro (Kambadur et al., 2006a; 2006b; 2006c; unpublished data). 
Therefore, subsequent in vivo studies commenced to test the efficacy of 
myostatin antagonists in different wound healing models.  
 
4.1.2. Development of the Muscle Burn Injury Model  
Wound healing is characterised by three broad stages, the inflammatory 
response, proliferation and remodelling. The inflammatory response was 
discussed in detail in Section 1.5 of this thesis. The proliferative phase involves 
the formation of granulation tissue to fill the wound area, particularly through 
fibroblast proliferation, collagen and extracellular matrix deposition and re-
epithilialisation. Once the formation of new tissue in the wound area is 
complete, the functionality of the tissue is restored in the remodelling phase. 
The three phases of wound healing often overlap, and numerous growth factors 
and cytokines are involved in regulating each step, thereby making it a very 
complex process. Furthermore, any disruptions to this coordinated wound 
healing process may cause further damage to the tissue, and hence delay repair   
(Greenhalgh, 1996; Li et al., 2007). Therefore, determining the mechanisms 
behind any therapy developed to improve wound healing is a difficult and time-
consuming process. 
 
Nevertheless, both acute and chronic wound healing models are widely used 
throughout the literature and can provide valuable information during the 
development of wound healing therapies.  As discussed in Section 1.6.4 of this 
thesis, Siriett et al. (2007) of the FMG group recently tested Mstn-ant1 using an 
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acute notexin injury model. The authors reported enhanced regeneration levels 
in Mstn-ant1-treated mice compared to placebo-treated mice. In addition, the 
Mstn-ant1-treated mice showed reduced levels of scarring after the injury, 
suggesting Mstn-ant1 was improving wound healing following the notexin 
injury. Similar results were also obtained when Mstn-ant1 was tested in 
sarcopenia, a chronic injury model, with the authors reporting improved wound 
healing and increased muscle strength of the aged mice (Siriett et al., 2007). An 
alternative myostatin antagonist, Mstn-ant3, has also been shown to attenuate 
muscle wasting in mdx mice, a murine model of the chronic Duchenne and 
Becker muscular dystrophies (Kambadur et al., 2006c).  
 
However, to confirm and further characterise the effects of these myostatin 
antagonists, auxiliary testing in a range of injury models is required, which 
provided the basis for this thesis. There is not a standardised protocol for a 
muscle burn injury in any of the published wound healing models. However, 
upon examining the plethora of literature on skin burn injuries, the burn injury is 
often classified as the most devastating injury a person can endure (Greenhalgh, 
1996), and therefore the ability to improve wound healing following a burn 
injury would be very valuable. For that reason, Orico Ltd. wanted to establish 
the potential of myostatin antagonists for the treatment of burn injuries by 
funding two different projects, which tested the effect of Mstn-ant4 on both skin 
and muscle burn injuries, with the muscle burn injury being the focus of this 
thesis.  
 
As discussed in Section 3.1, the murine muscle burn injury developed for this 
thesis was found to produce a very severe injury, more severe in fact than any 
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other acute injury model previously used by the FMG group at AgResearch Ltd. 
This was particularly evident when the frozen TA muscles were sectioned for 
histology. The burn injury made the tissue very fragile and therefore very 
difficult to section, particularly at days 2 and 4 post-injury. The FMG group at 
AgResearch Ltd. have not encountered any such difficulties when sectioning TA 
muscle samples subjected to an acute notexin or incision injury in the past 
(personal communication).  
 
In the case of skin burns, the degree of severity is classified as a first-, second-, 
third-, and in some instances, a fourth-degree burn. These levels relate to the 
depth of the burn injury through the layers of the skin, with sunburn being 
classified as a first-degree burn and a fourth-degree burn extending into 
underlying muscle or bone; and also to the extent of body surface area affected 
by the burn (Greenhalgh, 1996). This classification system can obviously not be 
applied to the burn injury developed for this thesis; however, one could estimate 
that the severity of the muscle burn injury would compare to at least a third-
degree skin burn.  
 
4.1.3. In vivo Trial 
The in vivo trial undertaken as part of this thesis was based on the notexin trial 
described by Siriett et al. (2007), as this also used an acute injury model. 
However, instead of extending the results of Mstn-ant1 reported by Siriett et al. 
(2007) to the burn injury model, Orico Ltd. wanted to test the efficacy of Mstn-
ant4, following its very promising results in vitro, for patent purposes.  
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As shown in Section 3.3 of this thesis, the in vivo trial did produce some 
promising results which supported the initial hypotheses and were consistent 
with the findings for Mstn-ant1 by Siriett et al. (2007), along with other studies 
using myostatin antagonists carried out by the FMG group at AgResearch Ltd. 
(Kambadur et al., 2006a; 2006b; 2006c). Firstly, the Mstn-ant4-treated mice 
recovered from the burn-induced loss of body weight earlier than the saline-
treated mice (see Section 3.3.1). Real-Time PCR also revealed a tendency for 
mighty expression to be higher in the burnt muscles of Mstn-ant4-treated mice 
than those of saline-treated mice. This confirmed the orginial hypothesis that 
because mighy is a downstream target of myostatin (Marshall et al., 2008), an 
inhibiton of myostatin function by the antagonist would result in an increase in 
mighty gene expression levels, above those of saline-treated mice during muscle 
regeneration following the burn injury. In addition, mighty expression levels 
increased significantly between days 2 and 4 post-injury, which is consistent 
with previous results obtained using both notexin and incision injury models 
(Senna Salerno et al., submitted).  
 
Although contradictory results for the expression of mighty were obtained from 
the Semi-Quantitative PCR results, Real-Time PCR is often considered to be a 
more sensitive and accurate technique. There are three phases to PCR 
amplifications, the exponential phase where doubling of the amplicon (product) 
occurs; the linear phase where the reaction components are being consumed, the 
reaction is slowing down and PCR products are beginning to degrade; and 
finally a plateau phase where the reaction has completely stopped and no more 
product is being made. Semi-Quantitative PCR detects the PCR amplification at 
the plateau phase, hence why it is often referred to as end-point PCR. In 
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contrast, Real-Time PCR allows PCR amplification to be detected during the 
early exponential growth phase of the reaction. Furthermore, the increase in 
SYBR Green fluorescent signal is directly proportional to the number of 
amplicons produced, explaining why Real-Time PCR is often considered a more 
accurate and sensitive technique. Therefore, by using a combination of both 
PCR techniques, a more comprehensive analysis of myogenic gene expression 
could be carried out (Kubista et al., 2006).  
 
The other very interesting result generated from this in vivo trial was found 
during the histological analysis of CFN. As discussed in Sections 1.7.2 and 
3.3.2.1, one of the key indicators of skeletal muscle regeneration is the presence 
of CFN in the muscle fibres (Brazelton et al., 2003). In theory, greater numbers 
of CFN and CFN number per muscle fibre correspond to increased levels of 
wound healing. Therefore, it was hypothesised that Mstn-ant4-treated mice 
would show higher levels of CFN and CFN per muscle fibre than saline-treated 
mice, when analysed by histological staining. Although no overall significant 
differences in CFN number or CFN to CFN fibre ratio were evident between the 
two treatment groups, there was a significant increase in the CFN to CFN fibre 
ratio in the burnt muscles of Mstn-ant4-treated mice at day 14 post-injury; 
however, this rapidly decreased after day 14 and closely followed the trend of 
the saline-treated mice for the remaining time points. This is a particularly 
important observation because the final subcutaneous injection of Mstn-ant4 
was administered on day 15 post-injury, and therefore this sudden decline in the 
CFN to CFN fibre ratio after day 14 in the burnt muscles of Mstn-ant4-treated 
mice may indicate that administration of the myostatin antagonist was 
terminated too early during the course of the in vivo trial.  
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Unfortunately, no other results obtained from the histological, gene expression, 
or immunocytochemical analyses obtained from the in vivo trial, supported these 
findings. However, if this study was repeated using optimised conditions, more 
promising results, similar to those of other myostatin antagonists (Kambadur et 
al., 2006a; 2006b; 2006c; Siriett et al., 2007), would be expected. To clarify, this 
was the first attempt using both the murine burn injury model and Mstn-ant4 for 
an in vivo trial. Although the in vivo trial was based on the notexin injury trial by 
Siriett et al. (2007), also an acute injury like the burn, the burn injury proved to 
be more severe than the notexin injury and every other injury model that has 
been used by the FMG group at AgResearch Ltd. Therefore, perhaps the 
schedule for administering Mstn-ant4 should have been modelled on the recent 
sarcopenia trial (Siriett et al., 2007) or mdx trial (Kambadur et al., 2006c), 
involving three injections per week for three weeks, thus supplying the 
antagonist for longer. This is supported by the CFN to CFN fibre ratio results, 
where the ratio in the Mstn-ant4-treated mice showed a sudden decline after day 
14 post-injury, suggesting that administration of Mstn-ant4 should be extended 
past day 15 post-injury, the final injection day for this in vivo trial.  
 
In addition, the burn injury may have been variable among animals as it was 
inflicted manually, with no way of consistently controlling the pressure used to 
apply the hot metal rod to the TA muscle. Furthermore, because of the wide 
range of time points that needed to be examined to follow the different healing 
milestones after the burn injury (because of its severity), all measurements were 
only based on three animals per treatment per time point. This is because the in 
vivo trial already involved ninety-six mice and it was not logistically possible to 
obtain any more animals that were of the same age. The prospect of inflicting 
 117 
 
burn injuries on both hind limbs of the mice was also investigated to double the 
amount of data that could be generated, but this was not approved by the 
Ruakura Animal Ethics Committee. Furthermore, samples were not able to be 
processed in duplicate. For example, first-strand cDNA synthesis would ideally 
have been performed in duplicate for each muscle sample which would have 
therefore allowed duplicate PCRs to be generated in order to minimise 
variability. Due to time restrictions this was not possible. Hence natural 
variation among animals and experimental samples may have obscured 
treatment differences. 
 
As a result of the limitation in animal number, there were also insufficient 
muscle samples to extract both RNA and protein separately, which may have 
given a more comprehensive assessment of the efficacy of Mstn-ant4 on muscle 
wound healing. To counteract this problem, an attempt was made to extract 
protein using the Trizol method detailed in Section 2.2.5.1, but this was 
unsuccessful, and due to time constraints the technique could not be 
standardised. However, a kit has now become available that enables RNA, DNA 
and protein to be extracted from a single tissue sample (Innovative Sciences 
Ltd.), which will be a useful tool for future in vivo studies of this kind. For this 
thesis however, the results of the in vivo trial were limited to only histology, 
immunocytochemistry and gene expression analyses using Semi-Quantitative 
PCR and Real-Time PCR. 
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4.2. Future Direction 
In summary, any further development of Mstn-ant4 as a pharmaceutical therapy 
for muscle wound healing and disease would need to have a very specific 
regimen designed according to the type of injury being treated. In the case of the 
burn injury used in this thesis, more frequent administration of Mstn-ant4 for an 
extended period of time would be suggested. The burn injury itself may also 
need to be further standardised to limit variability between animals. Perhaps the 
use of lasers to inflict the burn injury, as discussed in Section 3.1 of this thesis, 
could be investigated. Furthermore, a trial comparing the efficacy of Mstn-ant1 
and Mstn-ant4 on wound healing following the burn injury may be very useful. 
In addition, as Real-Time PCR is considered to be a more sensitive and accurate 
technique, Semi-Quantitative PCR would probably not be necessary for future 
studies. Historically only Semi-Quantitative PCR has been used by the FMG 
group at AgResearch, hence its inclusion in this thesis. However, due to the 
variability generated in these results, Real-Time PCR was then carried out. This 
is a fairly new technique being adopted by the FMG group at AgResearch and it 
is proving to be very time-efficient and accurate.   
 
Overall, Mstn-ant4 has shown potential to improve wound healing following a 
burn injury, and incorporating these suggestions into future studies would 
progress the development of Mstn-ant4 as a commercially viable pharmaceutical 
therapy.  
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Appendix 
1% Agarose 
0.5 g UltraPure agarose (Invitrogen) 
50 ml 1 x TAE  
Boiled until agarose is dissolved.  
1 µl 10 mg/ml ethidium bromide per 50 ml Agarose. 
 
10% Buffered Formalin 
32.5 g Na2HPO4 
20 g NaH2PO4.H2O 
500 ml formalin 
4.5 L H2O 
 
Coomassie Blue Stain 
2.5 g Coomassie Brilliant Blue R-250 
45% methanol 
10% acetic acid 
 
DEPC-treated water 
2 ml DEPC 
2 L MilliQ water 
Mixed overnight then autoclaved. 
 
DNA 1kb+ Ladder 
90 µl 10 x DNA loading dye 
810 µl MilliQ water 
100 µl 1 µg/ml 1kb+ ladder 
  
DNA Loading Dye (10 x) 
10 ml 50% glycerol 
2 ml 50 x TAE 
Bromophenol blue 
 
Eosin (1% solution) 
10 g Eosin Y 
1 L MilliQ water 
2.0 ml acetic acid (5% aqueous) 
1 crystal of thymol 
 
Gill’s Haematoxylin 
4.0 g Haematoxylin 
0.4 g sodium iodate 
35.2 g aluminium sulphate 
710 ml MilliQ water 
250 ml ethylene glycol 
40 ml glacial acetic acid 
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LB Broth 
20 g LB Broth Base 
1 L MilliQ water 
autoclaved 
 
PBS (Phosphate Buffered Saline) 
1 PBS tablet (Oxoid) 
100 ml MilliQ water 
 
PBS-T 
1 L PBS 
2 µl tween-20 
 
PBS-T + 0.2% BSA 
100ml PBS-T 
0.2 g BSA  
 
Scott’s tap-water 
2.0 g sodium bicarbonate 
20.0 g magnesium sulphate 
1 L MilliQ water 
1 crystal of thymol 
 
TAE (Tris-acetate EDTA) (1 x) 
400ml TAE (50 x) 
19.6 L DEPC-treated water 
 
TAE (50 x) 
242 g Tris (base) 
57.1 ml glacial acetic acid 
100 ml 0.5 M EDTA (ph 8.0) 
Made up to 1 L with MilliQ water 
 
Van Gieson Solution 
10 ml 1% aqueous acid fuchsin   
90 ml saturated Picric acid 
0.25 ml concentrated HCl 
 
Weigert’s Iron Haematoxylin Solution A 
1% haematoxylin in absolute alcohol 
 
Weigert’s Iron Haemotoxylin Solution B 
4 ml 30% Ag ferric chloride 
1 ml concentrated HCl 
100 ml distilled H2O 
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